Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
45 "Dong Il Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
IBD
Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao, on behalf of the Clinical Research Committee of the Asian Organization for Crohn’s and Colitis
Intest Res 2022;20(2):192-202.   Published online April 29, 2022
DOI: https://doi.org/10.5217/ir.2020.00150
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile the prevalence and pattern of CAM use among East Asian IBD patients and to identify factors associated with CAM use. We also compared physicians’ perspectives on CAM.
Methods
Patients with IBD from China, Japan, and South Korea were invited to complete questionnaires on CAM use. Patient demographic and clinical data were collected. Logistic regression analysis was applied for predictors of CAM use. Physicians from each country were asked about their opinion on CAM services or products.
Results
Overall, 905 patients with IBD participated in this study (China 232, Japan 255, and South Korea 418). Approximately 8.6% of patients with IBD used CAM services for their disease, while 29.7% of patients sought at least 1 kind of CAM product. Current active disease and Chinese or South Korean nationality over Japanese were independent predictors of CAM use. Chinese doctors were more likely to consider CAM helpful for patients with IBD than were Japanese and South Korean doctors.
Conclusions
In 8.6% and 29.7% of East Asian patients with IBD used CAM services and products, respectively, which does not differ from the prevalence in their Western counterparts. There is a significant gap regarding CAM usage among different Asian countries, not only from the patients’ perspective but also from the physicians’ point of view.

Citations

Citations to this article as recorded by  
  • Recent Perspective of Lactobacillus in Reducing Oxidative Stress to Prevent Disease
    Tingting Zhao, Haoran Wang, Zhenjiang Liu, Yang Liu, DeJi, Bin Li, Xiaodan Huang
    Antioxidants.2023; 12(3): 769.     CrossRef
  • The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
    Iason Psilopatis, Kleio Vrettou, Constantinos Giaginis, Stamatios Theocharis
    International Journal of Molecular Sciences.2023; 24(10): 8918.     CrossRef
  • 3,719 View
  • 161 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Intest Res 2022;20(4):452-463.   Published online March 11, 2022
DOI: https://doi.org/10.5217/ir.2021.00125
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Epidemiological data on steroid use in South Korean patients with inflammatory bowel disease (IBD) are limited. We documented the steroid use patterns in these patients, and whether physician education on appropriate steroid use affected these patterns.
Methods
ACTION was an observational cohort study conducted in adults (≥19 years) with IBD. A retrospective chart review was performed at baseline (cohort 1) and 1 year after physician training (cohort 2). Eligible cases with excessive or inappropriate steroid use were identified, along with any associated risk factors.
Results
Data were collected during May 2018-July 2019 from patients with Crohn’s disease (CD) and ulcerative colitis (UC) in cohort 1 (n=1,685) and cohort 2 (n=1,649). At baseline, 155 patients (9.2%) had received steroids within the previous 12 months, 46 (29.7%) of whom had used steroids excessively, 16 (34.8%) of these having inappropriately used excessive steroids. Although steroid exposure was similar in cohort 1 (9.2%) and cohort 2 (9.7%), the latter comprised fewer excessive steroid users (20.0% vs. 29.7%). Severe disease was associated with excessive steroid use in cases with UC, but not with CD.
Conclusions
Although, overall steroid use was relatively low in South Korean patients with IBD, one-third of steroid users used them excessively, and one-third among these used excessive steroids inappropriately. High disease activity was the main risk factor for excessive steroid use which may potentially be reduced by physician education, especially in cases with UC. Active screening to minimize excessive and inappropriate steroid use through physician education should be considered.

Citations

Citations to this article as recorded by  
  • The Reliability and Quality of Short Videos as a Source of Dietary Guidance for Inflammatory Bowel Disease: Cross-sectional Study
    Zixuan He, Zhijie Wang, Yihang Song, Yilong Liu, Le Kang, Xue Fang, Tongchang Wang, Xuanming Fan, Zhaoshen Li, Shuling Wang, Yu Bai
    Journal of Medical Internet Research.2023; 25: e41518.     CrossRef
  • Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
    Seulji Kim, Seong-Joon Koh
    Intestinal Research.2022; 20(4): 389.     CrossRef
  • 4,139 View
  • 449 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):350-360.   Published online July 23, 2021
DOI: https://doi.org/10.5217/ir.2021.00049
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods
A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results
A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions
ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.

Citations

Citations to this article as recorded by  
  • Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
    Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin,
    Journal of Crohn's and Colitis.2024; 18(3): 341.     CrossRef
  • Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
    Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
    United European Gastroenterology Journal.2024; 12(4): 459.     CrossRef
  • Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
    Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
    Health Science Reports.2024;[Epub]     CrossRef
  • Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
    Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
    Gut Pathogens.2024;[Epub]     CrossRef
  • Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
    Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
    Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-
    Therapeutic Advances in Gastroenterology.2023; 16: 175628482311681.     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Precision medicine and drug optimization in adult inflammatory bowel disease patients
    Sophie Vieujean, Edouard Louis
    Therapeutic Advances in Gastroenterology.2023; 16: 175628482311733.     CrossRef
  • Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
    Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2023; 38(5): 661.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
    Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
    Metabolites.2023; 14(1): 2.     CrossRef
  • Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
    Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
    Inflammatory Bowel Diseases.2022;[Epub]     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 7,555 View
  • 651 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
Inflammatory Bowel Diseases
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee
Intest Res 2021;19(3):323-331.   Published online August 18, 2020
DOI: https://doi.org/10.5217/ir.2020.00039
AbstractAbstract PDFPubReaderePub
Background/Aims
Infliximab (IFX) has proven effective as rescue therapy in steroid-refractory acute severe ulcerative colitis (ASUC), however, the long-term real-world data are scarce. Our study aimed to assess the long-term treatment outcomes of IFX in a real-life cohort.
Methods
We established a multicenter retrospective cohort of hospitalized patients with ASUC, who met Truelove and Witt’s criteria and received intravenous corticosteroid (IVCS) or IFX during index hospitalization between 2006 and 2016 in 5 university hospitals in Korea. The cohort was systematically followed up until colectomy, death or last follow-up visit.
Results
A total of 296 patients were followed up for a mean of 68.9 ± 44.0 months. During index hospitalization, 49 patients were treated with IFX; as rescue therapy for IVCS failure in 37 and as first-line medical therapy for ASUC in 12. All patients treated with IFX avoided colectomy during index hospitalization. The cumulative rates of rehospitalization and colectomy were 20.4% and 6.1% at 3 months and 39.6% and 18.8% at the end of follow-up, respectively. Patients treated with IFX presented with significantly shorter colectomy-free survival than IVCS responders (P= 0.04, log-rank test). Both cytomegalovirus colitis and Clostridioides difficile infection (CDI) were the significant predictors of colectomy in the overall study cohort (hazard ratios of 6.57 and 4.61, respectively). There were no fatalities.
Conclusions
Our real-world cohort study demonstrated that IFX is an effective therapeutic option in Korean patients with ASUC, irrespective of IFX indication. Aggressive vigilance for cytomegalovirus colitis and CDI is warranted for hospitalized patients with ASUC.

Citations

Citations to this article as recorded by  
  • Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis
    Christopher F D Li Wai Suen, Dean Seah, Matthew C Choy, Peter De Cruz
    Inflammatory Bowel Diseases.2024; 30(8): 1389.     CrossRef
  • Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
    Arshdeep Singh, Manjeet Kumar Goyal, Vandana Midha, Ramit Mahajan, Kirandeep Kaur, Yogesh Kumar Gupta, Dharmatma Singh, Namita Bansal, Ramandeep Kaur, Shivam Kalra, Omesh Goyal, Varun Mehta, Ajit Sood
    American Journal of Gastroenterology.2024; 119(7): 1365.     CrossRef
  • Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts
    Saman Sajjadi, Rebecca Svensson Neufert, Emilia Ruhr, Sebastian Tryggmo, Jan Marsal, Pamela Buchwald
    Scandinavian Journal of Gastroenterology.2023; 58(1): 15.     CrossRef
  • The role and prospect of tofacitinib in patients with ulcerative colitis
    Jun Lee
    Intestinal Research.2023; 21(1): 168.     CrossRef
  • Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
    Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
    Intestinal Research.2023; 21(2): 252.     CrossRef
  • Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
    Javier P Gisbert, María José García, María Chaparro
    Journal of Crohn's and Colitis.2023; 17(6): 972.     CrossRef
  • The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review
    Humza Awan, Urooj Fatima, Ryan Eaw, Naomi Knox, Laith Alrubaiy
    Cureus.2023;[Epub]     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
    Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim
    Intestinal Research.2023; 21(2): 244.     CrossRef
  • Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
    Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Yonsei Medical Journal.2023; 64(9): 541.     CrossRef
  • CURRENT STATUS, PROBLEMS AND PROSPECTS OF ULCERATIVE COLITIS MEDICAL CORRECTION (LITERATURE REVIEW)
    T. O. Briukhanova, O. A. Nakonechna, O. V Babenko
    Bulletin of Problems Biology and Medicine.2023; 1(3): 28.     CrossRef
  • Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
    Digestive Diseases and Sciences.2022; 67(7): 2866.     CrossRef
  • Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
    Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
    Intestinal Research.2022; 20(1): 101.     CrossRef
  • Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
    Journal of Personalized Medicine.2022; 12(3): 507.     CrossRef
  • Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Progress in Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection
    海丽 吴
    Advances in Clinical Medicine.2022; 12(08): 7627.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
    Jae Song Kim, Min Jung Geum, Eun Sun Son, Yun Mi Yu, Jae Hee Cheon, Kyeng Hee Kwon
    Gut and Liver.2022; 16(5): 736.     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions
    Tom Holvoet, Triana Lobaton, Pieter Hindryckx
    Clinical and Experimental Gastroenterology.2021; Volume 14: 71.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 5,770 View
  • 171 Download
  • 23 Web of Science
  • 23 Crossref
Close layer
Inflammatory bowel diseases
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Jong Pil Im, Takanori Kanai, Tatsuro Katsuno, Yoh Ishiguro, Makoto Nagaoka, Naoki Isogawa, Yinhua Li, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee, Robert Clare, Kenneth J. Gorelick, Fabio Cataldi, Mamoru Watanabe, Toshifumi Hibi
Intest Res 2020;18(1):45-55.   Published online January 30, 2020
DOI: https://doi.org/10.5217/ir.2019.00039
AbstractAbstract PDFPubReaderePub
Background/Aims
PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD).
Methods
OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients.
Results
In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7+ central memory CD4+ T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment.
Conclusions
In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509)

Citations

Citations to this article as recorded by  
  • Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
    Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
    Gut and Liver.2023; 17(5): 766.     CrossRef
  • Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
    Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
    Gut and Liver.2023; 17(6): 905.     CrossRef
  • Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
    Maximilian Wiendl, Emily Becker, Tanja M. Müller, Caroline J. Voskens, Markus F. Neurath, Sebastian Zundler
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Renin–angiotensin system in intestinal inflammation—Angiotensin inhibitors to treat inflammatory bowel diseases?
    Hanne Salmenkari, Riitta Korpela, Heikki Vapaatalo
    Basic & Clinical Pharmacology & Toxicology.2021; 129(3): 161.     CrossRef
  • Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents
    Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese
    Expert Opinion on Investigational Drugs.2021; 30(10): 1037.     CrossRef
  • Emerging therapeutic options in inflammatory bowel disease
    Jesus K Yamamoto-Furusho, Norma N Parra-Holguín
    World Journal of Gastroenterology.2021; 27(48): 8242.     CrossRef
  • 15,547 View
  • 188 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Review
IBD
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert WL Leong, the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis
Intest Res 2019;17(3):285-310.   Published online May 31, 2019
DOI: https://doi.org/10.5217/ir.2019.00026
AbstractAbstract PDFPubReaderePub
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn’s and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn’s disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.

Citations

Citations to this article as recorded by  
  • Progress on the mechanisms of Lactobacillus plantarum to improve intestinal barrier function in ulcerative colitis
    Yihui Liu, Gang Liu, Jun Fang
    The Journal of Nutritional Biochemistry.2024; 124: 109505.     CrossRef
  • Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps
    Kar Mun Chong, He Jiang, Elaine Ah Gi Lo, Wei-Zhen Hong, Emmett Tsz-Yeung Wong, Gek Cher Chan, Jiacai Cho
    Journal of Clinical Medicine.2024; 13(2): 451.     CrossRef
  • Modified Gegen Qinlian Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting Ferroptosis via Nrf2/GPX4 Pathway
    Jinke Huang, Jiaqi Zhang, Zhihong Liu, Jing Ma, Fengyun Wang, Xudong Tang, Muhammad Babar Khawar
    Journal of Food Quality.2024; 2024: 1.     CrossRef
  • Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
    Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C. Ng, Rupert W. Leong, Peeyush Kumar, Xin Hui Khoo, Govind K. Makharia, Jose Sollano, Pises Pisespongsa, Nazri Mustaffa, Rupa Banerjee, Alex Hwong‐Ruey Leow, Raja Affendi Raja Ali, Sai Wei Chuah
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1500.     CrossRef
  • Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
    Gut and Liver.2024; 18(3): 489.     CrossRef
  • Modified Gegen Qinlian Decoction modulated the gut microbiome and bile acid metabolism and restored the function of goblet cells in a mouse model of ulcerative colitis
    Jinke Huang, Jiaqi Zhang, Fengyun Wang, Xudong Tang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)
    Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
    Česko-slovenská pediatrie.2024; 79(4): 213.     CrossRef
  • Emerging Patterns of Inflammatory Bowel Disease in Sub-Saharan Africa: 175 Cases From an Inflammatory Bowel Disease Network
    Phoebe Hodges, Oluwafunmilayo Adeniyi, Smita Devani, Chinenye Nwoko, Opeyemi Owoseni, Kwadwo Gyebi Agyenim Boateng, Anthony Ocanit, Abdallah Muhofa, Nasiru Altine Dankiri, Babatunde Duduyemi, Zenahebezu Abay Alemayehu, Yusuf Musa, Eileen Micah, Pissi Kaba
    Journal of Crohn's and Colitis.2024;[Epub]     CrossRef
  • Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
    Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
    Advances in Digestive Medicine.2023; 10(1): 28.     CrossRef
  • A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
    Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
    Annals of Pharmacotherapy.2023; 57(9): 1053.     CrossRef
  • Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
    Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi
    Intestinal Research.2023; 21(1): 148.     CrossRef
  • Optimización del tratamiento de la colitis ulcerosa leve a moderada: Consenso Delphi CU-Forum
    Miquel Sans Cuffi, Federico Argüelles Arias, Ana Echarri Piudo, Daniel Ginard Vicens, Ana Gutiérrez Casbas, Ignacio Marín-Jiménez
    Gastroenterología y Hepatología.2023; 46(10): 784.     CrossRef
  • Study on the anti‐inflammatory effect of stachyose by inhibiting TLR4/NF‐κB signalling pathway in vitro and in vivo
    Songsong Jiang, Qian Li, Shiwen Han, Hengpeng Wang, Xinlei Tang, Tao Wang, Xiangren Meng
    Clinical and Experimental Pharmacology and Physiology.2023; 50(7): 573.     CrossRef
  • Physiologically‐Based Pharmacokinetic Modeling of Anti‐Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants
    Jiarui Chen, Rongfang Lin, Guimu Guo, Wanhong Wu, Meng Ke, Chengjie Ke, Pinfang Huang, Cuihong Lin
    Clinical Pharmacology & Therapeutics.2023; 114(6): 1254.     CrossRef
  • Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus
    Miquel Sans Cuffi, Federico Argüelles Arias, Ana Echarri Piudo, Daniel Ginard Vicens, Ana Gutiérrez Casbas, Ignacio Marín-Jiménez
    Gastroenterología y Hepatología (English Edition).2023; 46(10): 784.     CrossRef
  • Diagnosis of Crohn’s disease and ulcerative colitis using the microbiome
    Da-Yeon Kang, Jong-Lyul Park, Min-Kyung Yeo, Sang-Bum Kang, Jin-Man Kim, Ju Seok Kim, Seon-Young Kim
    BMC Microbiology.2023;[Epub]     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
    Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Journal of Crohn's and Colitis.2022; 16(2): 207.     CrossRef
  • Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
    Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe, Ben Kang
    Gut and Liver.2022; 16(1): 62.     CrossRef
  • Management of inflammatory bowel disease in the COVID-19 era
    Kyeong Ok Kim, Byung Ik Jang
    Intestinal Research.2022; 20(1): 3.     CrossRef
  • Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity
    Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Yoichi Kakuta, Hidezumi Kikuchi, Shogo Kawaguchi, Keisuke Hasui, Tetsuya Tatsuta, Daisuke Chinda, Tatsuya Mikami, Shinsaku Fukuda
    Intestinal Research.2022; 20(1): 90.     CrossRef
  • Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study
    Byong Duk Ye, Sung Noh Hong, Seung In Seo, Ye-Jee Kim, Jae Myung Cha, Kyoung Hoon Rhee, Hyuk Yoon, Young-Ho Kim, Kyung Ho Kim, Sun Yong Park, Seung Kyu Jeong, Ji Hyun Lee, Hyunju Park, Joo Sung Kim, Jong Pil Im, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim,
    Gut and Liver.2022; 16(2): 216.     CrossRef
  • Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
    Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
    Journal of Gastroenterology and Hepatology.2022; 37(6): 1004.     CrossRef
  • Implications of the COVID-19 Pandemic on the Management of Inflammatory Bowel Disease in the Low Resource Countries of Asia
    Partha Pal, Joyce Wing Yan Mak, Siew C Ng, Rupa Banerjee
    EMJ Gastroenterology.2022;[Epub]     CrossRef
  • The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
    Eun Ae Kang
    Gut and Liver.2022; 16(3): 487.     CrossRef
  • Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
    Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
    Inflammatory Bowel Diseases.2022; 28(Supplement): S16.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
    Eun Ae Kang, Jae Hee Cheon
    Gut and Liver.2022; 16(4): 501.     CrossRef
  • Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
    Jia-Feng Wu
    Gut and Liver.2022; 16(4): 515.     CrossRef
  • Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
    Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
    Gut and Liver.2022; 16(4): 567.     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
    Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian
    Gut and Liver.2022; 16(5): 726.     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial
    Katsumasa Nagano, Yuya Imai, Yoshifumi Ukyo, Taku Kobayashi, Seiji Yokoyama
    Inflammatory Intestinal Diseases.2022; 7(3-4): 155.     CrossRef
  • Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
    Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
    Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275.     CrossRef
  • Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy
    Takeshi Yasuda, Tomohisa Takagi, Jun Asai, Norito Katoh, Junya Kuroda, Yasumichi Kuwahara, Yukiko Morinaga, Eiichi Konishi, Kazuhiko Uchiyama, Yuji Naito, Yoshito Itoh
    Clinical Journal of Gastroenterology.2021; 14(1): 170.     CrossRef
  • Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
    Sun-Ho Lee, Margaret Walshe, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Tomer Greener, Adam V Weizman, Mark S Silverberg, Byong Duk Ye
    Inflammatory Bowel Diseases.2021; 27(9): 1452.     CrossRef
  • Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal
    J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, M.A. Martínez-Vázquez
    Revista de Gastroenterología de México.2021; 86(1): 70.     CrossRef
  • Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Gut and Liver.2021; 15(1): 92.     CrossRef
  • Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study
    Jeongseok Kim, Hyuk Yoon, Nayoung Kim, Kang-Moon Lee, Sung-Ae Jung, Chang Hwan Choi, Eun Soo Kim, Yunho Jung, Chang Soo Eun, Tae Oh Kim, Sang-Bum Kang, You Sun Kim, Geom-Seog Seo, Chang Kyun Lee, Jong Pil Im, Soo Jung Park, Dong Il Park, Byong Duk Ye
    Inflammatory Bowel Diseases.2021; 27(12): 1931.     CrossRef
  • Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease
    J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, M.A. Martínez-Vázquez
    Revista de Gastroenterología de México (English Edition).2021; 86(1): 70.     CrossRef
  • Early course of newly diagnosed moderate‐to‐severe ulcerative colitis in Korea: Results from a hospital‐based inception cohort study (MOSAIK)
    Jin Young Yoon, Jae Myung Cha, Chang Kyun Lee, Young Sook Park, Kyu Chan Huh, Jeong Eun Shin, You Sun Kim, Chang Soo Eun, Soon Man Yoon, Jae Hee Cheon, Young Soo Park, Byong Duk Ye, YoungJa Lee, Youngdoe Kim, Hyo Jong Kim
    Journal of Gastroenterology and Hepatology.2021; 36(8): 2149.     CrossRef
  • Role of Oxidative Stress and Inflammatory Cytokines (TNF-α and IL-6) in Acetic Acid-Induced Ulcerative Colitis in Rats: Ameliorated by Otostegia fruticosa
    Mohd Nazam Ansari, Najeeb Ur Rehman, Aman Karim, Gamal A. Soliman, Majid A. Ganaie, Mohammad Raish, Abubaker M. Hamad
    Life.2021; 11(3): 195.     CrossRef
  • Clinical features and treatment of inflammatory bowel disease in a low-incidence area
    Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
    Medicine.2021; 100(10): e25090.     CrossRef
  • Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
    Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2021; 15(2): 232.     CrossRef
  • Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
    Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
    Gut and Liver.2021; 15(3): 375.     CrossRef
  • Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational stud
    Min Young Park, Yong Sik Yoon, Jong Lyul Lee, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Chang Sik Yu
    Stem Cell Research & Therapy.2021;[Epub]     CrossRef
  • Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease
    Hoon Gil Jo, Geom Seog Seo
    The Korean Journal of Gastroenterology.2021; 78(1): 31.     CrossRef
  • Differentiating between Intestinal Tuberculosis and Crohn’s Disease May Be Complicated by Multidrug-resistant Mycobacterium tuberculosis
    Seung Wook Hong, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    The Ewha Medical Journal.2021; 44(3): 93.     CrossRef
  • Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
    Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Therapeutic Advances in Gastroenterology.2021;[Epub]     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
    Hyo Yeop Song, Geom Seog Seo
    Journal of the Korean Medical Association.2021; 64(9): 605.     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Clinical Characteristics and Long-term Prognosis of Elderly-Onset Ulcerative Colitis in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
    Sang Hyoung Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Hyunju Park, Joo Sung Kim, Jong Pil Im, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Gut and Liver.2021; 15(5): 742.     CrossRef
  • Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
    Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im, Chang Hwan Choi
    Gut and Liver.2021; 15(5): 752.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
    Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin-Biroulet
    Drugs.2021; 81(16): 1859.     CrossRef
  • Is Multidrug-resistant Extrapulmonary Tuberculosis Important? If So, What Is Our Strategy?
    Seong-Eun Kim
    The Ewha Medical Journal.2021; 44(4): 148.     CrossRef
  • Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
    You Sun Kim
    Intestinal Research.2021; 19(4): 357.     CrossRef
  • Another Piece of Evidence for Early Administration of Biologics in Children with Crohn's Disease Who Start as an Inflammatory Phenotype
    Hyuk Yoon
    Gut and Liver.2021; 15(6): 791.     CrossRef
  • Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
    Jin Wook Lee, Eun Mi Song, Sung-Ae Jung, Sung Hoon Jung, Kwang Woo Kim, Seong-Joon Koh, Hyun Jung Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn’s Disease Using RNA Sequencing Data
    Soo-Kyung Park, Sangsoo Kim, Gi-Young Lee, Sung-Yoon Kim, Wan Kim, Chil-Woo Lee, Jong-Lyul Park, Chang-Hwan Choi, Sang-Bum Kang, Tae-Oh Kim, Ki-Bae Bang, Jaeyoung Chun, Jae-Myung Cha, Jong-Pil Im, Kwang-Sung Ahn, Seon-Young Kim, Dong-Il Park
    Diagnostics.2021; 11(12): 2365.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine
    Soo-Youn Lee
    Annals of Laboratory Medicine.2020; 40(2): 95.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea
    Yoon Suk Jung
    Gut and Liver.2020; 14(1): 3.     CrossRef
  • Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
    Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
    Intestinal Research.2020; 18(1): 18.     CrossRef
  • Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn’s Disease Receiving Anti-tumour Necrosis Factor Therapy
    Soo Min Noh, Eun Hye Oh, Seong Ho Park, Jung Bok Lee, Jin Yong Kim, Jae Cheol Park, Jeongseok Kim, Nam Seok Ham, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beyong Duk Ye
    Journal of Crohn's and Colitis.2020; 14(9): 1231.     CrossRef
  • Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey
    Sun-Ho Lee, Kiju Chang, Ki Seok Seo, Yun Kyung Cho, Eun Mi Song, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Intestinal Research.2020; 18(2): 192.     CrossRef
  • Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota
    Zhongmei Sun, Junxiang Li, Yi Dai, Wenting Wang, Rui Shi, Zhibin Wang, Panghua Ding, Qiongqiong Lu, Hui Jiang, Wenjing Pei, Xingjie Zhao, Yi Guo, Jiali Liu, Xiang Tan, Tangyou Mao
    Frontiers in Microbiology.2020;[Epub]     CrossRef
  • Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Yonsei Medical Journal.2020; 61(5): 382.     CrossRef
  • Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea
    Jae Myung Cha, Sang Hyoung Park, Kyoung Hoon Rhee, Sung Noh Hong, Young-Ho Kim, Seung In Seo, Kyung Ho Kim, Seung Kyu Jeong, Ji Hyun Lee, Sun Yong Park, Hyunju Park, Joo Sung Kim, Jong Pil Im, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Gut.2020; 69(8): 1432.     CrossRef
  • Inflammatory Bowel Disease – Non-biological treatment
    Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
    Pharmacological Research.2020; 160: 105075.     CrossRef
  • Use of small bowel capsule endoscopy in clinical practice: how has it performed?
    Seong Ran Jeon
    The Korean Journal of Internal Medicine.2020; 35(4): 854.     CrossRef
  • Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2020; 35(5): 1104.     CrossRef
  • Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
    Jung Min Kim, Da Hye Kim, Hyo Jeong Park, Hyun Woo Ma, I Seul Park, Mijeong Son, So Youn Ro, Seokmann Hong, Hyo Kyung Han, Soo Jeong Lim, Seung Won Kim, Jae Hee Cheon
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
    Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
  • Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
    Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089.     CrossRef
  • NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine‐induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India
    Rupa Banerjee, Vishnubhotla Venkata Ravikanth, Partha Pal, Govardhan Bale, Urmila Steffie Avanthi, Idan Goren, B. Ganesh Girish, Sasikala Mitnala, D. Nageshwar Reddy
    Alimentary Pharmacology & Therapeutics.2020; 52(11-12): 1683.     CrossRef
  • 28,317 View
  • 931 Download
  • 77 Web of Science
  • 80 Crossref
Close layer
Commentary
IBD
A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study
Chang Kyun Lee, Kang-Moon Lee, Dong Il Park, Sung-Ae Jung, Yoon Tae Jeen, Young Sook Park, Hyo Jong Kim, the MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID)
Intest Res 2019;17(1):1-5.   Published online January 25, 2019
DOI: https://doi.org/10.5217/ir.2019.00005
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
    Hyuk Yoon, Young Soo Park, Jeong Eun Shin, Byong Duk Ye, Chang Soo Eun, Soon Man Yoon, Jae Myung Cha, You Sun Kim, Kyu Chan Huh, Young Sook Park, Jae Hee Cheon, Eun Suk Jung, Youngdoe Kim, Su Young Jung
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
    Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    Gut and Liver.2022; 16(1): 138.     CrossRef
  • Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year
    Ik Hyun Jo, Kang-Moon Lee, Dae Bum Kim, Ji Won Kim, Jun Lee, Yoon Tae Jeen, Tae-Oh Kim, Joo Sung Kim, Jae Jun Park, Sung Noh Hong, Dong Il Park, Hyun-Soo Kim, Yoo Jin Lee, Youngdoe Kim
    Gut and Liver.2022; 16(3): 384.     CrossRef
  • Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
    Jung Won Lee
    Gut and Liver.2022; 16(3): 317.     CrossRef
  • Early course of newly diagnosed moderate‐to‐severe ulcerative colitis in Korea: Results from a hospital‐based inception cohort study (MOSAIK)
    Jin Young Yoon, Jae Myung Cha, Chang Kyun Lee, Young Sook Park, Kyu Chan Huh, Jeong Eun Shin, You Sun Kim, Chang Soo Eun, Soon Man Yoon, Jae Hee Cheon, Young Soo Park, Byong Duk Ye, YoungJa Lee, Youngdoe Kim, Hyo Jong Kim
    Journal of Gastroenterology and Hepatology.2021; 36(8): 2149.     CrossRef
  • Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
    Ju-Young Shin, Hye-Min Park, Min-Young Lee, Ja-Young Jeon, Hyun-Jeong Yoo, Byong Duk Ye
    Gut and Liver.2021; 15(6): 867.     CrossRef
  • Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
    Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
    Gut and Liver.2021; 15(6): 942.     CrossRef
  • Anxiety and Depression in Patients with Inflammatory Bowel Diseases: The First Step toward Proper Management
    Jung Won Lee
    Gut and Liver.2020; 14(4): 395.     CrossRef
  • Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
    Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
    Gut and Liver.2020; 14(4): 459.     CrossRef
  • Quantitative Proteomic Analysis of the Expression of SARS-CoV-2 Receptors in the Gut of Patients with Chronic Enterocolitis
    Jihye Park, Daeun Jeong, Youn Wook Chung, Da Hye Kim, Jae Hee Cheon, Ji-Hwan Ryu
    Yonsei Medical Journal.2020; 61(10): 891.     CrossRef
  • 7,303 View
  • 191 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Original Articles
Colorectal neoplasia
Development and validation of a scoring system for advanced colorectal neoplasm in young Korean subjects less than age 50 years
Ji Yeon Kim, Sungkyoung Choi, Taesung Park, Seul Ki Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi, Dong Il Park
Intest Res 2019;17(2):253-264.   Published online November 20, 2018
DOI: https://doi.org/10.5217/ir.2018.00062
AbstractAbstract PDFPubReaderePub
Background/Aims
Colorectal cancer incidence among patients aged ≤50 years is increasing. This study aimed to develop and validate an advanced colorectal neoplasm (ACRN) screening model for young adults aged <50 years in Korea.
Methods
This retrospective cross-sectional study included 59,575 consecutive asymptomatic Koreans who underwent screening colonoscopy between 2003 and 2012 at a single comprehensive health care center. Young Adult Colorectal Screening (YCS) score was developed as an optimized risk stratification model for ACRN using multivariate analysis and was internally validated. The predictive power and diagnostic performance of YCS score was compared with those of Asia-Pacific Colorectal Screening (APCS) and Korean Colorectal Screening (KCS) scores.
Results
41,702 and 17,873 subjects were randomly allocated into the derivation and validation cohorts, respectively, by examination year. ACRN prevalence was 0.9% in both cohorts. YCS score comprised sex, age, alcohol, smoking, obesity, glucose metabolism abnormality, and family history of CRC, with score ranges of 0 to 10. In the validation cohort, ACRN prevalence was 0.6% in the low-risk tier (score, 0–4), 1.5% in the moderate-risk tier (score, 5–7), and 3.4% in the high-risk tier (score, 8–10). ACRN risk increased 2.5-fold (95%CI, 1.8–3.4) in the moderate-risk tier and 5.8-fold (95%CI, 3.4–9.8) in the high-risk tier compared with the low-risk tier. YCS score identified better balanced accuracy (53.9%) than APCS (51.5%) and KCS (50.7%) scores and had relatively good discriminative power (area under the curve=0.660).
Conclusions
YCS score based on clinical and laboratory risk factors was clinically effective and beneficial for predicting ACRN risk and targeting screening colonoscopy in adults aged <50 years.

Citations

Citations to this article as recorded by  
  • Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review
    Mai Ngoc Luu, Nhi Ai Trinh, Truc Le Thanh Tran, Thinh Phuong Dang, Toru Hiyama, Duc Trong Quach
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1000.     CrossRef
  • Updated epidemiology of gastrointestinal cancers in East Asia
    Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong
    Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271.     CrossRef
  • From Algorithms to Clinical Utility: A Systematic Review of Individualized Risk Prediction Models for Colorectal Cancer
    Deborah Jael Herrera, Wessel van de Veerdonk, Daiane Maria Seibert, Moges Muluneh Boke, Claudia Gutiérrez-Ortiz, Nigus Bililign Yimer, Karen Feyen, Allegra Ferrari, Guido Van Hal
    Gastrointestinal Disorders.2023; 5(4): 549.     CrossRef
  • Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
    Han Hee Lee
    Clinical Endoscopy.2022; 55(2): 315.     CrossRef
  • Is early-onset cancer an emerging global epidemic? Current evidence and future implications
    Tomotaka Ugai, Naoko Sasamoto, Hwa-Young Lee, Mariko Ando, Mingyang Song, Rulla M. Tamimi, Ichiro Kawachi, Peter T. Campbell, Edward L. Giovannucci, Elisabete Weiderpass, Timothy R. Rebbeck, Shuji Ogino
    Nature Reviews Clinical Oncology.2022; 19(10): 656.     CrossRef
  • Strategies for colorectal cancer screening and post-polypectomy surveillance for young adults under age 50
    Yoon Suk Jung
    Precision and Future Medicine.2021; 5(2): 69.     CrossRef
  • How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy
    Ji Eun Na, Eun Ran Kim
    The Ewha Medical Journal.2021; 44(4): 122.     CrossRef
  • The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review
    Marta Puzzono, Alessandro Mannucci, Simone Grannò, Raffaella Alessia Zuppardo, Andrea Galli, Silvio Danese, Giulia Martina Cavestro
    Cancers.2021; 13(23): 5933.     CrossRef
  • Association between waist circumference and risk of colorectal neoplasia in normal‐weight adults
    Yoon Suk Jung, Nam Hee Kim, Hyo‐Joon Yang, Soo‐Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2020; 35(1): 43.     CrossRef
  • Risk prediction rule for advanced neoplasia on screening colonoscopy for average-risk individuals
    Ala I Sharara, Ali El Mokahal, Ali H Harb, Natalia Khalaf, Fayez S Sarkis, Mustapha M El-Halabi, Nabil M Mansour, Ahmad Malli, Robert Habib
    World Journal of Gastroenterology.2020; 26(37): 5705.     CrossRef
  • Risk Factors Associated With Young-Onset Colorectal Adenomas and Cancer: A Systematic Review and Meta-Analysis of Observational Research
    Genevieve Breau, Ursula Ellis
    Cancer Control.2020; 27(1): 107327482097667.     CrossRef
  • Prevalence and risk factors of colorectal cancer in Asia
    Martin CS Wong, Hanyue Ding, Jingxuan Wang, Paul SF Chan, Junjie Huang
    Intestinal Research.2019; 17(3): 317.     CrossRef
  • 8,385 View
  • 162 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
WITHDRAWN:Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members
Soo-Kyung Park, Tadakazu Hisamatsu, Zhihua Ran, Shu-Chen Wei, Dong Il Park
Received June 12, 2018  Accepted October 6, 2018  Published online November 12, 2018  
DOI: https://doi.org/10.5217/ir.2018.00084

Citations

Citations to this article as recorded by  
  • Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan
    Muna Oqal, Bushra Hijazi, Abdelrahim Alqudah, Ahmad Al-Smadi, Basima A Almomani, Roaa Alnajjar, Majd Abu Ghunaim, Mohammad Irshaid, Aroob Husam, Gergely Feher
    International Journal of Clinical Practice.2022; 2022: 1.     CrossRef
  • 65,535 View
  • 64 Download
  • 1 Crossref
Close layer
Special Review
IBD
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S. Puri, Suk-Kyun Yang
Intest Res 2018;16(1):4-16.   Published online January 18, 2018
DOI: https://doi.org/10.5217/ir.2018.16.1.4
AbstractAbstract PDFPubReaderePub

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised 2 parts: risk of TB infection Recommendaduring anti-TNF therapy, and screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  
  • Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
    Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
    Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
  • (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
    Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
    Clinical Microbiology and Infection.2024; 30(8): 989.     CrossRef
  • Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
    Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C. Ng, Rupert W. Leong, Peeyush Kumar, Xin Hui Khoo, Govind K. Makharia, Jose Sollano, Pises Pisespongsa, Nazri Mustaffa, Rupa Banerjee, Alex Hwong‐Ruey Leow, Raja Affendi Raja Ali, Sai Wei Chuah
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1500.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients
    Flora Maria Lorenzo Fortes, Raquel Rocha, Genoile Oliveira Santana
    World Journal of Gastroenterology.2023; 29(9): 1536.     CrossRef
  • Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
    Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    Clinical Endoscopy.2023; 56(2): 239.     CrossRef
  • Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
    Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
    ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
  • Intestinal tuberculosis can masquerade as Crohn’s disease: A teachable moment
    Pooja KC, Madhur Bhattarai, Subodh Adhikari, Prakriti Parajuli, Sujata Bhandari, Himal Bikram Bhattarai, Niraj Kumar Sharma, Shailendra Karki, Suryakiran Acharya, Bibhusan Basnet
    SAGE Open Medical Case Reports.2023;[Epub]     CrossRef
  • The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
    Yuya Sugiyama, Nobuhiro Ueno, Shion Tachibana, Yu Kobayashi, Yuki Murakami, Takahiro Sasaki, Aki Sakatani, Keitaro Takahashi, Katsuyoshi Ando, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura, Mikihiro Fujiya
    Medicine.2023; 102(28): e34331.     CrossRef
  • Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
    Sayan Malakar, Srikanth Kothalkar, Umair Shamsul Hoda, Uday C Ghoshal
    Cureus.2023;[Epub]     CrossRef
  • Crohn’s disease and intestinal tuberculosis: challenging from every angle
    Andreia Guimarães, João Gama, Luis Curvo-Semedo, António Canaveira Manso
    BMJ Case Reports.2023; 16(12): e254400.     CrossRef
  • Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
    Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Increased Risk of Infection With High Infliximab Trough Level
    Suprabhat Giri, Harish Darak
    Journal of Clinical Gastroenterology.2022; 56(4): 374.     CrossRef
  • Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
    Journal of Personalized Medicine.2022; 12(3): 507.     CrossRef
  • Evidence-Based Commentary: Testing and Treating Latent Tuberculosis Before Starting Biologics and Small Molecules in Patients with Inflammatory Bowel Disease
    Rinkalben Kakadiya, Vishal Sharma
    Journal of Gastrointestinal Infections.2022; 12(02): 128.     CrossRef
  • Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
    Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
    Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
    Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
  • Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
    Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
    Intestinal Research.2021; 19(4): 419.     CrossRef
  • Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
    Lingna Ye, Thomas P. Chapman, Zhenzhen Wen, Lang Lin, Yun Qiu, Zhanju Liu, Zhihua Ran, Jiaming Qian, Kaichun Wu, Xiang Gao, Pinjin Hu, Minhu Chen, Simon P. L. Travis, Qian Cao
    Alimentary Pharmacology & Therapeutics.2021; 53(3): 390.     CrossRef
  • Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
    Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
    Gut and Liver.2020; 14(6): 685.     CrossRef
  • Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Hosim Soh, Jaeyoung Chun, Kyungdo Han, Seona Park, Gukhwan Choi, Jihye Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2019; 13(3): 333.     CrossRef
  • Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center
    Mafalda Sousa, Inês Ladeira, Ana Ponte, Carlos Fernandes, Adélia Rodrigues, Ana P. Silva, João Silva, Catarina Gomes, Edgar Afeto, João Carvalho
    European Journal of Gastroenterology & Hepatology.2019; 31(9): 1099.     CrossRef
  • The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
    Joyce WY Mak, Joseph JY Sung
    Journal of Gastroenterology and Hepatology.2019; 34(8): 1269.     CrossRef
  • Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
    Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
    International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
  • Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
    Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
    The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
  • Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)

    Intestinal Research.2018; 16(2): 178.     CrossRef
  • High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
    Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
    Intestinal Research.2018; 16(4): 588.     CrossRef
  • Risk of infection associated with anti-TNF-α therapy
    Mario Fernández-Ruiz, José María Aguado
    Expert Review of Anti-infective Therapy.2018; 16(12): 939.     CrossRef
  • 9,556 View
  • 203 Download
  • 28 Web of Science
  • 28 Crossref
Close layer
Special Review: Consensus on TB in IBD
IBD
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S. Puri, Suk-Kyun Yang
Intest Res 2018;16(1):17-25.   Published online January 18, 2018
DOI: https://doi.org/10.5217/ir.2018.16.1.17
AbstractAbstract PDFPubReaderePub

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised 3 parts: management of latent TB in preparation for anti-TNF therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  
  • Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
    Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
    Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
  • Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
    Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
    Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
    Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
    ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
    Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis
    Shuhei Hosomi, Naoko Sugita, Atsushi Kanamori, Masaki Ominami, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Yasuhiro Fujiwara
    Clinical Journal of Gastroenterology.2022; 15(3): 592.     CrossRef
  • Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study
    Fen Liu, Jian Tang, Lingna Ye, Jinyu Tan, Yun Qiu, Fan Hu, Jinshen He, Baili Chen, Yao He, Zhirong Zeng, Ren Mao, Qian Cao, Xiang Gao, Minhu Chen
    Clinical and Translational Gastroenterology.2022; 13(6): e00493.     CrossRef
  • Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
    Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
    Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho Jung
    The Korean Journal of Gastroenterology.2020; 75(1): 1.     CrossRef
  • Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
    Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
    The Korean Journal of Gastroenterology.2020; 75(1): 29.     CrossRef
  • Preoperative hypoalbuminemia is an independent risk factor for postoperative complications in Crohn's disease patients with normal BMI: A cohort study
    Xiaolong Ge, Huaying Liu, Shasha Tang, Yan Wu, Yipeng Pan, Wei Liu, Weilin Qi, Lingna Ye, Qian Cao, Wei Zhou
    International Journal of Surgery.2020; 79: 294.     CrossRef
  • Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
    Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
    Gut and Liver.2020; 14(6): 685.     CrossRef
  • Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
    Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
    International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
  • Translating the gut microbiome: ready for the clinic?
    Susan V. Lynch, Siew C. Ng, Fergus Shanahan, Herbert Tilg
    Nature Reviews Gastroenterology & Hepatology.2019; 16(11): 656.     CrossRef
  • Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
    Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
    The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
  • Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)

    Intestinal Research.2018; 16(2): 178.     CrossRef
  • A rare case of disseminated histoplasmosis in a patient with Crohn’s disease on immunosuppressive treatment
    Bhavesh Bhut, Akshay Kulkarni, Varnika Rai, Vinita Agrawal, Abhai Verma, Manoj Jain, Rungmei S K Marak, Ajai Kumar Dixit, Uday C Ghoshal
    Indian Journal of Gastroenterology.2018; 37(5): 472.     CrossRef
  • High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
    Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
    Intestinal Research.2018; 16(4): 588.     CrossRef
  • 6,852 View
  • 176 Download
  • 17 Web of Science
  • 20 Crossref
Close layer
Original Articles
Endoscopy
Three-year colonoscopy surveillance after polypectomy in Korea: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter prospective study
Won Seok Choi, Dong Soo Han, Chang Soo Eun, Dong Il Park, Jeong-Sik Byeon, Dong-Hoon Yang, Sung-Ae Jung, Sang Kil Lee, Sung Pil Hong, Cheol Hee Park, Suck-Ho Lee, Jeong-Seon Ji, Sung Jae Shin, Bora Keum, Hyun Soo Kim, Jung Hye Choi, Sin-Ho Jung
Intest Res 2018;16(1):126-133.   Published online January 18, 2018
DOI: https://doi.org/10.5217/ir.2018.16.1.126
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Colonoscopic surveillance is currently recommended after polypectomy owing to the risk of newly developed colonic neoplasia. However, few studies have investigated colonoscopy surveillance in Asia. This multicenter and prospective study was undertaken to assess the incidence of advanced adenoma based on baseline adenoma findings at 3 years after colonoscopic polypectomy.

Methods

A total of 1,323 patients undergoing colonoscopic polypectomy were prospectively assigned to 3-year colonoscopy surveillance at 11 tertiary endoscopic centers. Relative risks for advanced adenoma after 3 years were calculated according to baseline adenoma characteristics.

Results

Among 1,323 patients enrolled, 387 patients (29.3%) were followed up, and the mean follow-up interval was 31.0±9.8 months. The percentage of patients with advanced adenoma on baseline colonoscopy was higher in the surveillance group compared to the non-surveillance group (34.4% vs. 25.7%). Advanced adenoma recurrence was observed in 17 patients (4.4%) at follow-up. The risk of advanced adenoma recurrence was 2 times greater in patients with baseline advanced adenoma than in those with baseline non-advanced adenoma, though the difference was not statistically significant (6.8% [9/133] vs. 3.1% [8/254], P=0.09). Advanced adenoma recurrence was observed only in males and in subjects aged ≥50 years. In contrast, adenoma recurrence was observed in 187 patients (48.3%) at follow-up. Male sex, older age (≥50 years), and multiple adenomas (≥3) at baseline were independent risk factors for adenoma recurrence.

Conclusions

A colonoscopy surveillance interval of 3 years in patients with baseline advanced adenoma can be considered appropriate.

Citations

Citations to this article as recorded by  
  • When should patients take simethicone orally before colonoscopy for avoiding bubbles: A single-blind, randomized controlled study
    Woohyuk Jung, Gyu Man Oh, Jae Hyun Kim, Youn Jung Choi, Min Young Son, Kyoungwon Jung, Sung Eun Kim, Won Moon, Moo In Park, Seun Ja Park
    Medicine.2023; 102(19): e33728.     CrossRef
  • Comparison of the efficacy and safety between oral sulfate tablet and polyethylene glycol for bowel preparation before colonoscopy according to age
    Jae Hyun Kim, Yong Eun Park, Tae Oh Kim, Jongha Park, Gyu Man Oh, Won Moon, Seun Ja Park
    Medicine.2022; 101(27): e29884.     CrossRef
  • Optimization of the surveillance strategy in patients with colorectal adenomas: A combination of clinical parameters and index colonoscopy findings
    Chan Hyuk Park, Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2021; 36(4): 974.     CrossRef
  • Postgastrectomy gastric cancer patients are at high risk for colorectal neoplasia: a case control study
    Tae-Geun Gweon, Kyu-Tae Yoon, Chang Hyun Kim, Jin-Jo Kim
    Intestinal Research.2021; 19(2): 239.     CrossRef
  • Risk of developing metachronous advanced colorectal neoplasia after resection of low-risk diminutive versus small adenomas
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Gastrointestinal Endoscopy.2020; 91(3): 622.     CrossRef
  • Optimal Colonoscopic Surveillance Interval After Normal Baseline Screening Colonoscopy
    Jian Dong, Minman Wu, Jiarong Miao, Rana Sami Ullah Khan, Tao Zhi, Tianmei Zhang, Xue Li, Yashi Peng, Gang Yang, Qiong Nan
    Gastroenterology Nursing.2020; 43(3): 225.     CrossRef
  • Comparative systematic review and meta-analysis of 1- to 5-mm versus 6- to 9-mm adenomas on the risk of metachronous advanced colorectal neoplasia
    Yoon Suk Jung, Tae Jun Kim, Eunwoo Nam, Chan Hyuk Park
    Gastrointestinal Endoscopy.2020; 92(3): 692.     CrossRef
  • Appropriate Surveillance Interval after Colonoscopic Polypectomy in Patients Younger than 50 Years
    Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Impact of obesity and metabolic abnormalities on the risk of metachronous colorectal neoplasia after polypectomy in men
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2019; 34(9): 1504.     CrossRef
  • What Is Appropriate Upper Endoscopic Interval Among Dyspeptic Patients With Previously Normal Endoscopy? A Multicenter Study With Bayesian Change Point Analysis
    Jong Wook Kim, Kee Wook Jung, Joong Goo Kwon, Jung Bok Lee, Jong Kyu Park, Ki Bae Bang, Chung Hyun Tae, Jung Hwan Oh
    Journal of Neurogastroenterology and Motility.2019; 25(4): 544.     CrossRef
  • Risk of Developing Metachronous Advanced Colorectal Neoplasia After Polypectomy in Patients With Multiple Diminutive or Small Adenomas
    Nam Hee Kim, Yoon Suk Jung, Mi Yeon Lee, Jung Ho Park, Dong Il Park, Chong Il Sohn
    American Journal of Gastroenterology.2019; 114(10): 1657.     CrossRef
  • 8,936 View
  • 79 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population?
Soo-Kyung Park, Hae Lim Baek, Junghee Yu, Ji Yeon Kim, Hyo-Joon Yang, Yoon Suk Jung, Kyu Yong Choi, Hungdai Kim, Hyung Ook Kim, Kyung Uk Jeong, Ho-Kyung Chun, Kyungeun Kim, Dong Il Park
Intest Res 2017;15(4):495-501.   Published online October 23, 2017
DOI: https://doi.org/10.5217/ir.2017.15.4.495
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Colorectal cancer (CRC) screening using stool DNA was recently found to yield good detection rates. A multi-target stool DNA test (Cologuard®, Exact Sciences), including methylated genes has been recently approved by the U.S. Food and Drug Administration. The aim of this study was to validate these aberrantly methylated genes as stool-based DNA markers for detecting CRC and colorectal advanced adenoma (AA) in the Korean population.

Methods

A single-center study was conducted in 36 patients with AA; 35 patients with CRC; and 40 endoscopically diagnosed healthy controls using CRC screening colonoscopy. The methylation status of the SFRP2, TFPI2, NDRG4, and BMP3 promoters was investigated blindly using bisulfate-modified stool DNA obtained from 111 participants. Methylation status was investigated by methylation-specific polymerase chain reaction.

Results

Methylated SFRP2, TFPI2, NDRG4, and BMP3 promoters were detected in 60.0%, 31.4%, 68.8%, and 40.0% of CRC samples and in 27.8%, 27.8%, 27.8%, and 33.3% of AA samples, respectively. The sensitivities obtained using 4 markers to detect CRC and AA were 94.3% and 72.2%, respectively. The specificity was 55.0%.

Conclusions

Our results demonstrate that the SFRP2, TFPI2, NDRG4, and BMP3 promoter methylation analysis of stool sample DNA showed high sensitivity but low specificity for detecting CRC and AA. Because of the low specificity, 4 methylated markers might not be sufficient for CRC screening in the Korean population. Further large-scale studies are required to validate the methylation of these markers in the Asian population and to find new markers for the Asian population.

Citations

Citations to this article as recorded by  
  • DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine
    Jingxin Ye, Jianfeng Zhang, Weifeng Ding
    Exploration of Targeted Anti-tumor Therapy.2024; 5(1): 34.     CrossRef
  • Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration
    Chang Kyo Oh, Young-Seok Cho
    Intestinal Research.2024; 22(2): 131.     CrossRef
  • Tissue factor pathway inhibitor-2 (TFPI-2)—an underappreciated partaker in cancer and metastasis
    Marek Z. Wojtukiewicz, Marta Mysliwiec, Anna Tokajuk, Joanna Kruszewska, Barbara Politynska, Anmbreen Jamroze, Anna M. Wojtukiewicz, Dean G. Tang, Kenneth V. Honn
    Cancer and Metastasis Reviews.2024;[Epub]     CrossRef
  • Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis
    Yudith Annisa Ayu Rezkitha, Nur Syahadati Retno Panenggak, Maria Inge Lusida, Raissa Virgy Rianda, Isna Mahmudah, Aditya Doni Pradana, Tomohisa Uchida, Muhammad Miftahussurur
    Journal of Medicine and Life.2024; 17(1): 4.     CrossRef
  • In Silico Gene Prioritization Highlights the Significance of Bone Morphogenetic Protein 4 (BMP4) Promoter Methylation across All Methylation Clusters in Colorectal Cancer
    Daša Jevšinek Skok, Nina Hauptman
    International Journal of Molecular Sciences.2023; 24(16): 12692.     CrossRef
  • Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
    Huafeng Jiang, Senjun Zhou, Gang Li
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions
    Yuan Li, Bin Li, Rou Jiang, Leen Liao, Chunting Zheng, Jie Yuan, Liuhong Zeng, Kunling Hu, Yuyu Zhang, Weijian Mei, Zhigang Hong, Binyi Xiao, Lingheng Kong, Kai Han, Jinghua Tang, Wu Jiang, Zhizhong Pan, Shenyan Zhang, Peirong Ding
    Cancer Medicine.2023; 12(21): 20626.     CrossRef
  • Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples
    Patricio Órdenes, Claudio Carril Pardo, Roberto Elizondo-Vega, Karina Oyarce
    Biology.2023; 13(1): 15.     CrossRef
  • Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics
    Francesco Ferrara, Sofia Zoupanou, Elisabetta Primiceri, Zulfiqur Ali, Maria Serena Chiriacò
    Biosensors and Bioelectronics.2022; 196: 113698.     CrossRef
  • Novel Diagnostic Biomarkers in Colorectal Cancer
    Aneta L. Zygulska, Piotr Pierzchalski
    International Journal of Molecular Sciences.2022; 23(2): 852.     CrossRef
  • Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis
    Roya Dolatkhah, Saeed Dastgiri, Mohammad Asghari Jafarabadi, Hossein Mashhadi Abdolahi, Mohammad Hossein Somi
    Gastroenterología y Hepatología.2022; 45(10): 753.     CrossRef
  • Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers
    Maartje Massen, Kim Lommen, Kim A. D. Wouters, Johan Vandersmissen, Wim van Criekinge, James G. Herman, Veerle Melotte, Leo J. Schouten, Manon van Engeland, Kim M. Smits
    Clinical Epigenetics.2022;[Epub]     CrossRef
  • DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine
    Nayeralsadat Fatemi, Sascha Tierling, Hamidreza Aboulkheyr Es, Maryam Varkiani, Ehsan Nazemalhosseini Mojarad, Hamid Asadzadeh Aghdaei, Jörn Walter, Mehdi Totonchi
    International Journal of Cancer.2022; 151(12): 2068.     CrossRef
  • Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis
    Roya Dolatkhah, Saeed Dastgiri, Mohammad Asghari Jafarabadi, Hossein Mashhadi Abdolahi, Mohammad Hossein Somi
    Gastroenterología y Hepatología (English Edition).2022; 45(10): 753.     CrossRef
  • Performance evaluation of stool DNA methylation tests in colorectal cancer screening: a systematic review and meta‐analysis
    Mahir Gachabayov, Edward Lebovics, Aram Rojas, Daniel M Felsenreich, Rifat Latifi, Roberto Bergamaschi
    Colorectal Disease.2021; 23(5): 1030.     CrossRef
  • Fecal Multidimensional Assay for Non-Invasive Detection of Colorectal Cancer: Fecal Immunochemical Test, Stool DNA Mutation, Methylation, and Intestinal Bacteria Analysis
    Shaobo Mo, Hui Wang, Lingyu Han, Wenqiang Xiang, Weixing Dai, Pengfei Zhao, Fengchun Pei, Zhixi Su, Chengcheng Ma, Qi Li, Zhimin Wang, Sanjun Cai, Hao Wang, Rui Liu, Guoxiang Cai
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC
    Glenn Rademakers, Maartje Massen, Alexander Koch, Muriel X. Draht, Nikkie Buekers, Kim A. D. Wouters, Nathalie Vaes, Tim De Meyer, Beatriz Carvalho, Gerrit A. Meijer, James G. Herman, Kim M. Smits, Manon van Engeland, Veerle Melotte
    Clinical Epigenetics.2021;[Epub]     CrossRef
  • Advances in Early Detection of Colorectal Cancer: A Focus on Non-invasive Biomarkers
    Nadia El Kadmiri
    Current Drug Targets.2021; 22(9): 1043.     CrossRef
  • RETRACTED: Using Comorbidity Pattern Analysis to Detect Reliable Methylated Genes in Colorectal Cancer Verified by Stool DNA Test
    Yi-Chiao Cheng, Po-Hsien Wu, Yen-Ju Chen, Cing-Han Yang, Jhen-Li Huang, Yu-Ching Chou, Pi-Kai Chang, Chia-Cheng Wen, Shu-Wen Jao, Hsin-Hui Huang, Yi-Hsuan Tsai, Tun-Wen Pai
    Genes.2021; 12(10): 1539.     CrossRef
  • Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia
    Jiayi Mu, Yanqin Huang, Shanrong Cai, Qilong Li, Yongmao Song, Ying Yuan, Suzhan Zhang, Shu Zheng
    Clinica Chimica Acta.2020; 501: 42.     CrossRef
  • Epigenetics of colorectal cancer: biomarker and therapeutic potential
    Gerhard Jung, Eva Hernández-Illán, Leticia Moreira, Francesc Balaguer, Ajay Goel
    Nature Reviews Gastroenterology & Hepatology.2020; 17(2): 111.     CrossRef
  • Novel biomarkers for the diagnosis and prognosis of colorectal cancer
    Hyung-Hoon Oh, Young-Eun Joo
    Intestinal Research.2020; 18(2): 168.     CrossRef
  • Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review
    Janhavi R. Raut, Zhong Guan, Petra Schrotz-King, Hermann Brenner
    Clinical Epigenetics.2020;[Epub]     CrossRef
  • Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer
    Haochang Hu, Tiangong Wang, Ranran Pan, Yong Yang, Bin Li, Cong Zhou, Jun Zhao, Yi Huang, Shiwei Duan
    Pathology & Oncology Research.2019; 25(2): 567.     CrossRef
  • BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients
    Parisa Rokni, Afsaneh Mojtabanezhad Shariatpanahi, Ebrahim Sakhinia, Mohammad Amin Kerachian
    Genes & Genomics.2018; 40(4): 423.     CrossRef
  • Syndecan-2 Methylation as a New Biomarker for Early Detection of Colorectal Neoplasm
    Ji Hyun Kim, Sung Chul Park
    Gut and Liver.2018; 12(5): 479.     CrossRef
  • 6,328 View
  • 94 Download
  • 26 Web of Science
  • 26 Crossref
Close layer
Miss rate of colorectal neoplastic polyps and risk factors for missed polyps in consecutive colonoscopies
Nam Hee Kim, Yoon Suk Jung, Woo Shin Jeong, Hyo-Joon Yang, Soo-Kyung Park, Kyuyong Choi, Dong Il Park
Intest Res 2017;15(3):411-418.   Published online June 12, 2017
DOI: https://doi.org/10.5217/ir.2017.15.3.411
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Colonoscopic polypectomy is the best diagnostic and therapeutic tool to detect and prevent colorectal neoplasms. However, previous studies have reported that 17% to 28% of colorectal polyps are missed during colonoscopy. We investigated the miss rate of neoplastic polyps and the factors associated with missed polyps from quality-adjusted consecutive colonoscopies.

Methods

We reviewed the medical records of patients who were found to have colorectal polyps at a medical examination center of the Kangbuk Samsung Hospital between March 2012 and February 2013. Patients who were referred to a single tertiary academic medical center and underwent colonoscopic polypectomy on the same day were enrolled in our study. The odds ratios (ORs) associated with polyp-related and patient-related factors were evaluated using logistic regression analyses.

Results

A total of 463 patients and 1,294 neoplastic polyps were analyzed. The miss rates for adenomas, advanced adenomas, and carcinomas were 24.1% (312/1,294), 1.2% (15/1,294), and 0% (0/1,294), respectively. Flat/sessile-shaped adenomas (adjusted OR, 3.62; 95% confidence interval [CI], 2.40–5.46) and smaller adenomas (adjusted OR, 5.63; 95% CI, 2.84– 11.15 for ≤5 mm; adjusted OR, 3.18; 95% CI, 1.60–6.30 for 6–9 mm, respectively) were more frequently missed than pedunculated/sub-pedunculated adenomas and larger adenomas. In patients with 2 or more polyps compared with only one detected (adjusted OR, 2.37; 95% CI, 1.55–3.61 for 2–4 polyps; adjusted OR, 11.52; 95% CI, 4.61–28.79 for ≥5 polyps, respectively) during the first endoscopy, the risk of missing an additional polyp was significantly higher.

Conclusions

One-quarter of neoplastic polyps was missed during colonoscopy. We encourage endoscopists to detect smaller and flat or sessile polyps by using the optimal withdrawal technique.

Citations

Citations to this article as recorded by  
  • UM-Net: Rethinking ICGNet for polyp segmentation with uncertainty modeling
    Xiuquan Du, Xuebin Xu, Jiajia Chen, Xuejun Zhang, Lei Li, Heng Liu, Shuo Li
    Medical Image Analysis.2025; 99: 103347.     CrossRef
  • Future Implications of Artificial Intelligence in Medical Education
    Forrest Bohler, Nikhil Aggarwal, Garrett Peters, Varna Taranikanti
    Cureus.2024;[Epub]     CrossRef
  • Polyp Segmentation Using a Hybrid Vision Transformer and a Hybrid Loss Function
    Evgin Goceri
    Journal of Imaging Informatics in Medicine.2024; 37(2): 851.     CrossRef
  • SAEFormer: stepwise attention emphasis transformer for polyp segmentation
    Yicai Tan, Lei Chen, Chudong Zheng, Hui Ling, Xinshan Lai
    Multimedia Tools and Applications.2024; 83(30): 74833.     CrossRef
  • Polyp Segmentation With the FCB-SwinV2 Transformer
    Kerr Fitzgerald, Jorge Bernal, Aymeric Histace, Bogdan J. Matuszewski
    IEEE Access.2024; 12: 38927.     CrossRef
  • Leveraging a realistic synthetic database to learn Shape-from-Shading for estimating the colon depth in colonoscopy images
    Josué Ruano, Martín Gómez, Eduardo Romero, Antoine Manzanera
    Computerized Medical Imaging and Graphics.2024; 115: 102390.     CrossRef
  • DHAFormer: Dual-channel hybrid attention network with transformer for polyp segmentation
    Xuejie Huang, Liejun Wang, Shaochen Jiang, Lianghui Xu, Chung-Ming Lo
    PLOS ONE.2024; 19(7): e0306596.     CrossRef
  • The Findings of Index Colonoscopy in Patients with Post-colonoscopy Colorectal Cancer (PCCRC)
    Seiji Kimura
    Nihon Daicho Komonbyo Gakkai Zasshi.2024; 77(8): 457.     CrossRef
  • Detection of various gastrointestinal tract diseases through a deep learning method with ensemble ELM and explainable AI
    Md. Faysal Ahamed, Md. Nahiduzzaman, Md. Rabiul Islam, Mansura Naznine, Mohamed Arselene Ayari, Amith Khandakar, Julfikar Haider
    Expert Systems with Applications.2024; 256: 124908.     CrossRef
  • A Hessian-Based Technique for Specular Reflection Detection and Inpainting in Colonoscopy Images
    Khaled ELKarazle, Valliappan Raman, Caslon Chua, Patrick Then
    IEEE Journal of Biomedical and Health Informatics.2024; 28(8): 4724.     CrossRef
  • Trends in colorectal cancer surgical resection rates during the screening era: a retrospective study in Italy
    Manuel Zorzi, Lucia Calciano, Nicola Gennaro, Laura Memo, Silvia Rizzato, Carmen Stocco, Emanuele D L Urso, Silvia Negro, Gaya Spolverato, Salvatore Pucciarelli, Marta Sbaraglia, Stefano Guzzinati
    BMJ Open Gastroenterology.2024; 11(1): e001434.     CrossRef
  • The Interplay among Wnt/β-catenin Family Members in Colorectal Adenomas and Surrounding Tissues
    Domenica Lucia D’Antonio, Fabiana Fantini, Carmelo Moscatello, Alessio Ferrone, Stefano Scaringi, Rosa Valanzano, Ferdinando Ficari, Konstantinos Efthymakis, Matteo Neri, Gitana Maria Aceto, Maria Cristina Curia
    Biomedicines.2024; 12(8): 1730.     CrossRef
  • Review: Risk assessment of liver and biliary cancer mortality through detection of high risk polyps at colonoscopies
    Abeera Tariq, Fnu Hafeezullah, Abdul Basit Khan
    Digestive and Liver Disease.2024;[Epub]     CrossRef
  • Trivariate Joint Modeling for Family Data with Longitudinal Counts, Recurrent Events and a Terminal Event with Application to Lynch Syndrome
    Jingwei Lu, Grace Y. Yi, Denis Rustand, Patrick Parfrey, Laurent Briollais, Yun‐hee Choi
    Statistics in Medicine.2024;[Epub]     CrossRef
  • A complete benchmark for polyp detection, segmentation and classification in colonoscopy images
    Yael Tudela, Mireia Majó, Neil de la Fuente, Adrian Galdran, Adrian Krenzer, Frank Puppe, Amine Yamlahi, Thuy Nuong Tran, Bogdan J. Matuszewski, Kerr Fitzgerald, Cheng Bian, Junwen Pan, Shijle Liu, Gloria Fernández-Esparrach, Aymeric Histace, Jorge Bernal
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Effectiveness of artificial intelligence assisted colonoscopy on adenoma and polyp miss rate: A meta-analysis of tandem RCTs
    M. Maida, G. Marasco, M.H.J. Maas, D. Ramai, M. Spadaccini, E. Sinagra, A. Facciorusso, P.D. Siersema, C. Hassan
    Digestive and Liver Disease.2024;[Epub]     CrossRef
  • CafeNet: A Novel Multi‐Scale Context Aggregation and Multi‐Level Foreground Enhancement Network for Polyp Segmentation
    Zhanlin Ji, Xiaoyu Li, Zhiwu Wang, Haiyang Zhang, Na Yuan, Xueji Zhang, Ivan Ganchev
    International Journal of Imaging Systems and Technology.2024;[Epub]     CrossRef
  • An optimized deep focused U-Net model for image segmentation
    Haroon Haider Khan, Majid Iqbal Khan
    Neural Computing and Applications.2024;[Epub]     CrossRef
  • Efficacy of colonoscopic re-examination across the entire colon: a randomized controlled trial
    Dong Seok Lee, Jeong-Seon Ji, Tae-Geun Gweon, Myeongsook Seo, Hwang Choi
    Surgical Endoscopy.2024;[Epub]     CrossRef
  • An ensemble framework of deep neural networks for colorectal polyp classification
    Farah Younas, Muhammad Usman, Wei Qi Yan
    Multimedia Tools and Applications.2023; 82(12): 18925.     CrossRef
  • Effect of computer‐aided colonoscopy on adenoma miss rates and polyp detection: A systematic review and meta‐analysis
    Sagar Shah, Nathan Park, Nabil El Hage Chehade, Anastasia Chahine, Marc Monachese, Amelie Tiritilli, Zain Moosvi, Ronald Ortizo, Jason Samarasena
    Journal of Gastroenterology and Hepatology.2023; 38(2): 162.     CrossRef
  • Comparison of missed adenomas in deep-sedated and unsedated colonoscopy: A multicenter retrospective study
    Yue Sui, Yanhua Zheng, Qing Wang, Jieping Lv, Hongjin Wang, Qing Wen, Zhenzhen Wang, Guanfeng Wang, Hui Jia, Fengzhen Cao, Naping Wang, Junlian Hao, Yiping Zhang, Xiaopeng Wu, Haihua Chen, Junhui Lu, Xing Chen
    European Journal of Internal Medicine.2023; 110: 48.     CrossRef
  • A Real-Time Polyp-Detection System with Clinical Application in Colonoscopy Using Deep Convolutional Neural Networks
    Adrian Krenzer, Michael Banck, Kevin Makowski, Amar Hekalo, Daniel Fitting, Joel Troya, Boban Sudarevic, Wolfgang G. Zoller, Alexander Hann, Frank Puppe
    Journal of Imaging.2023; 9(2): 26.     CrossRef
  • Robust real-time polyp detection system design based on YOLO algorithms by optimizing activation functions and hyper-parameters with artificial bee colony (ABC)
    Ahmet Karaman, Ishak Pacal, Alper Basturk, Bahriye Akay, Ufuk Nalbantoglu, Seymanur Coskun, Omur Sahin, Dervis Karaboga
    Expert Systems with Applications.2023; 221: 119741.     CrossRef
  • Efficient Gastrointestinal Disease Classification Using Pretrained Deep Convolutional Neural Network
    Muhammad Nouman Noor, Muhammad Nazir, Sajid Ali Khan, Oh-Young Song, Imran Ashraf
    Electronics.2023; 12(7): 1557.     CrossRef
  • The basis and implications of diverging approaches to colorectal adenoma surveillance in the West
    Tsai‐Wing Ow, Edmund Tse, Guru Iyngkaran, Finlay Macrae
    Internal Medicine Journal.2023; 53(4): 635.     CrossRef
  • Investigation of artificial intelligence integrated fluorescence endoscopy image analysis with indocyanine green for interpretation of precancerous lesions in colon cancer
    Jinhyeon Kim, Hajung Kim, Yong Sik Yoon, Chan Wook Kim, Seung-Mo Hong, Sungjee Kim, Doowon Choi, Jihyun Chun, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Sun Young Kim, Seung-Jae Myung,
    PLOS ONE.2023; 18(5): e0286189.     CrossRef
  • Linked color imaging versus conventional white light colonoscopy for the detection of colorectal polyps
    Jun Watanabe, Takeshi Kanno, Eiichi Kakehi, Kazuma Rifu, Takehiro Kagaya, Kazuhiko Kotani, Yuki Kataoka
    Cochrane Database of Systematic Reviews.2023;[Epub]     CrossRef
  • A dynamic loss function for improved semantic segmentation
    Haroon Haider Khan, Majid Iqbal Khan
    Soft Computing.2023;[Epub]     CrossRef
  • Improved Colorectal Polyp Segmentation Using Enhanced MA-NET and Modified Mix-ViT Transformer
    Khaled Elkarazle, Valliappan Raman, Patrick Then, Caslon Chua
    IEEE Access.2023; 11: 69295.     CrossRef
  • Localization and Classification of Gastrointestinal Tract Disorders Using Explainable AI from Endoscopic Images
    Muhammad Nouman Noor, Muhammad Nazir, Sajid Ali Khan, Imran Ashraf, Oh-Young Song
    Applied Sciences.2023; 13(15): 9031.     CrossRef
  • Near-Infrared Imaging of Colonic Adenomas In Vivo Using Orthotopic Human Organoids for Early Cancer Detection
    Xiaoli Wu, Chun-Wei Chen, Sangeeta Jaiswal, Tse-Shao Chang, Ruoliu Zhang, Michael K. Dame, Yuting Duan, Hui Jiang, Jason R. Spence, Sen-Yung Hsieh, Thomas D. Wang
    Cancers.2023; 15(19): 4795.     CrossRef
  • Comparative Analysis of Machine Learning Models for Image Detection of Colonic Polyps vs. Resected Polyps
    Adriel Abraham, Rejath Jose, Jawad Ahmad, Jai Joshi, Thomas Jacob, Aziz-ur-rahman Khalid, Hassam Ali, Pratik Patel, Jaspreet Singh, Milan Toma
    Journal of Imaging.2023; 9(10): 215.     CrossRef
  • Additional 30-Second Observation of the Right-Sided Colon for Missed Polyp Detection With Texture and Color Enhancement Imaging Compared with Narrow Band Imaging: A Randomized Trial
    Naohisa Yoshida, Yoshikazu Inagaki, Yutaka Inada, Reo Kobayashi, Yuri Tomita, Hikaru Hashimoto, Osamu Dohi, Ryohei Hirose, Ken Inoue, Takaaki Murakami, Yasutaka Morimoto, Yusuke Okuyama, Yukiko Morinaga, Yoshito Itoh
    American Journal of Gastroenterology.2023;[Epub]     CrossRef
  • Wide-field endoscope accessory for multiplexed fluorescence imaging
    Gaoming Li, Miki Lee, Tse-Shao Chang, Joonyoung Yu, Haijun Li, Xiyu Duan, Xiaoli Wu, Sangeeta Jaiswal, Shuo Feng, Kenn R. Oldham, Thomas D. Wang
    Scientific Reports.2023;[Epub]     CrossRef
  • Analysis and research on intelligent manufacturing medical product design and intelligent hospital system dynamics based on machine learning under big data
    Zongxin Liu, Jiaozi Pu
    Enterprise Information Systems.2022; 16(2): 193.     CrossRef
  • Application of multimedia network english listening model based on confidence learning algorithm for speech recognition
    Yingting Zhang, Zewei Huang
    International Journal of System Assurance Engineering and Management.2022; 13(S3): 1091.     CrossRef
  • Unified Focal loss: Generalising Dice and cross entropy-based losses to handle class imbalanced medical image segmentation
    Michael Yeung, Evis Sala, Carola-Bibiane Schönlieb, Leonardo Rundo
    Computerized Medical Imaging and Graphics.2022; 95: 102026.     CrossRef
  • Colonoscopic image synthesis with generative adversarial network for enhanced detection of sessile serrated lesions using convolutional neural network
    Dan Yoon, Hyoun-Joong Kong, Byeong Soo Kim, Woo Sang Cho, Jung Chan Lee, Minwoo Cho, Min Hyuk Lim, Sun Young Yang, Seon Hee Lim, Jooyoung Lee, Ji Hyun Song, Goh Eun Chung, Ji Min Choi, Hae Yeon Kang, Jung Ho Bae, Sungwan Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Endo‐wing versus transparent hood‐assisted colonoscopy for colorectal adenoma detection: A randomized controlled trial
    Kazuya Miyaguchi, Yoshikazu Tsuzuki, Nobutaka Hirooka, Rie Shiomi, Hideki Ohgo, Hidetomo Nakamoto, Hiroyuki Imaeda
    Journal of Gastroenterology and Hepatology.2022; 37(4): 766.     CrossRef
  • AI and Clinical Decision Making: The Limitations and Risks of Computational Reductionism in Bowel Cancer Screening
    Saleem Ameen, Ming-Chao Wong, Kwang-Chien Yee, Paul Turner
    Applied Sciences.2022; 12(7): 3341.     CrossRef
  • BlazeNeo: Blazing Fast Polyp Segmentation and Neoplasm Detection
    Nguyen S. An, Phan N. Lan, Dao V. Hang, Dao V. Long, Tran Q. Trung, Nguyen T. Thuy, Dinh V. Sang
    IEEE Access.2022; 10: 43669.     CrossRef
  • Establishment and evaluation of a nomogram predicting risks of missed diagnoses of colorectal polyps
    Xiaobo Wang, Haiyang Guo, Yong Tang, Lin Chen, Xianfei Wang
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Evaluation of the efficacy of 1 L polyethylene glycol plus ascorbic acid and an oral sodium sulfate solution: A multi-center, prospective randomized controlled trial
    Jung Hun Woo, Hoon Sup Koo, Dae Sung Kim, Jeong Eun Shin, Yunho Jung, Kyu Chan Huh
    Medicine.2022; 101(35): e30355.     CrossRef
  • Correlation between Surrogate Quality Indicators for Adenoma Detection Rate and Adenoma Miss Rate in Qualified Colonoscopy, CORE Study: KASID Multicenter Study
    Jae Hee Han, Hyun Gun Kim, Eu Mi Ahn, Suyeon Park, Seong Ran Jeon, Jae Myung Cha, Min Seob Kwak, Yunho Jung, Jeong Eun Shin, Hyun Deok Shin, Young-Seok Cho
    Gut and Liver.2022; 16(5): 716.     CrossRef
  • Endoscopy Lifetime Systems Architecture: Scoping Out the Past to Diagnose the Future Technology
    Craig M. Browning, Robert Cloutier, Thomas C. Rich, Silas J. Leavesley
    Systems.2022; 10(5): 189.     CrossRef
  • A stacking-based artificial intelligence framework for an effective detection and localization of colon polyps
    Carina Albuquerque, Roberto Henriques, Mauro Castelli
    Scientific Reports.2022;[Epub]     CrossRef
  • Effect of water exchange method on adenoma miss rate of patients undergoing selective polypectomy: A randomized controlled trial
    Gui Ren, Xiangping Wang, Hui Luo, Shaowei Yao, Shuhui Liang, Linhui Zhang, Tao Dong, Long Chen, Qin Tao, Xuegang Guo, Ying Han, Yanglin Pan
    Digestive and Liver Disease.2021; 53(5): 625.     CrossRef
  • Feature Point Tracking-Based Localization of Colon Capsule Endoscope
    Jürgen Herp, Ulrik Deding, Maria M. Buijs, Rasmus Kroijer, Gunnar Baatrup, Esmaeil S. Nadimi
    Diagnostics.2021; 11(2): 193.     CrossRef
  • Risk factors associated with missed colorectal lesions in colonoscopy and impact of colonoscopy with anesthesia on miss rate
    Haibin Dong, Yutang Ren, Bo Jiang
    Scandinavian Journal of Gastroenterology.2021; 56(4): 484.     CrossRef
  • Diagnostic Accuracy of Artificial Intelligence and Computer-Aided Diagnosis for the Detection and Characterization of Colorectal Polyps: Systematic Review and Meta-analysis
    Scarlet Nazarian, Ben Glover, Hutan Ashrafian, Ara Darzi, Julian Teare
    Journal of Medical Internet Research.2021; 23(7): e27370.     CrossRef
  • Focus U-Net: A novel dual attention-gated CNN for polyp segmentation during colonoscopy
    Michael Yeung, Evis Sala, Carola-Bibiane Schönlieb, Leonardo Rundo
    Computers in Biology and Medicine.2021; 137: 104815.     CrossRef
  • Comparison of adenoma detection by colonoscopy between polypectomy performed during both insertion and withdrawal versus during withdrawal only: a multicenter, randomized, controlled trial
    Tae-Geun Gweon, Seung-Woo Lee, Jeong-Seon Ji, Jeong Rok Lee, Joon Sung Kim, Byung-Wook Kim, Hwang Choi
    Surgical Endoscopy.2020; 34(12): 5461.     CrossRef
  • Water Exchange (WE) and Quality Improvement—Enhanced Advanced Adenoma Detection
    Felix W. Leung, Malcolm Koo, Hui Jia, Joseph W. Leung, Sergio Cadoni, Premysl Falt, Yu-Hsi Hsieh, Chi-Tan Hu, Yanglin Pan, Franco Radaelli
    Journal of Clinical Gastroenterology.2020; 54(3): 212.     CrossRef
  • Tubular Locomotion and Positioning Using Tip Eversion for Endoscopy
    Ankit Saxena, Eric M. Pauli, Randy S. Haluck, Barry Fell, Jason Moore
    Journal of Medical Devices.2020;[Epub]     CrossRef
  • Molecular Aspects of Colorectal Adenomas: The Interplay among Microenvironment, Oxidative Stress, and Predisposition
    Gitana Maria Aceto, Teresa Catalano, Maria Cristina Curia
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Impact of Inadequate Bowel Cleansing on Colonoscopic Findings in Routine Screening Practice
    Tobias Niedermaier, Efrat L. Amitay, Anton Gies, Korbinian Weigl, Michael Hoffmeister, Hermann Brenner
    Clinical and Translational Gastroenterology.2020; 11(4): e00169.     CrossRef
  • Polyp Segmentation with Fully Convolutional Deep Neural Networks—Extended Evaluation Study
    Yunbo Guo, Jorge Bernal, Bogdan J. Matuszewski
    Journal of Imaging.2020; 6(7): 69.     CrossRef
  • A comprehensive review of deep learning in colon cancer
    Ishak Pacal, Dervis Karaboga, Alper Basturk, Bahriye Akay, Ufuk Nalbantoglu
    Computers in Biology and Medicine.2020; 126: 104003.     CrossRef
  • Artificial intelligence technologies for the detection of colorectal lesions: The future is now
    Simona Attardo, Viveksandeep Thoguluva Chandrasekar, Marco Spadaccini, Roberta Maselli, Harsh K Patel, Madhav Desai, Antonio Capogreco, Matteo Badalamenti, Piera Alessia Galtieri, Gaia Pellegatta, Alessandro Fugazza, Silvia Carrara, Andrea Anderloni, Piet
    World Journal of Gastroenterology.2020; 26(37): 5606.     CrossRef
  • Training a computer-aided polyp detection system to detect sessile serrated adenomas using public domain colonoscopy videos
    Taibo Li, Jeremy R. Glissen Brown, Kelovoulos Tsourides, Nadim Mahmud, Jonah M. Cohen, Tyler M. Berzin
    Endoscopy International Open.2020; 08(10): E1448.     CrossRef
  • PICCOLO White-Light and Narrow-Band Imaging Colonoscopic Dataset: A Performance Comparative of Models and Datasets
    Luisa F. Sánchez-Peralta, J. Blas Pagador, Artzai Picón, Ángel José Calderón, Francisco Polo, Nagore Andraka, Roberto Bilbao, Ben Glover, Cristina L. Saratxaga, Francisco M. Sánchez-Margallo
    Applied Sciences.2020; 10(23): 8501.     CrossRef
  • Efficacy of 1.2 L polyethylene glycol plus ascorbic acid for bowel preparations
    Hiroyuki Tamaki, Teruyo Noda, Masahiro Morita, Akina Omura, Atsushi Kubo, Chikara Ogawa, Toshihiro Matsunaka, Mitsushige Shibatoge
    World Journal of Clinical Cases.2019; 7(4): 452.     CrossRef
  • Multimodal endoscopic system based on multispectral and photometric stereo imaging and analysis
    Jihun Kim, Hasan Al Faruque, Sewoong Kim, Eunjoo Kim, Jae Youn Hwang
    Biomedical Optics Express.2019; 10(5): 2289.     CrossRef
  • Blue Laser Imaging, Blue Light Imaging, and Linked Color Imaging for the Detection and Characterization of Colorectal Tumors
    Naohisa Yoshida, Osamu Dohi, Ken Inoue, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Ken Inoue, Yuji Naito, Yutaka Inada, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Rafiz Abdul Rani, Yoshito Itoh
    Gut and Liver.2019; 13(2): 140.     CrossRef
  • Application of OCT in the Gastrointestinal Tract
    Nicholas S. Samel, Hiroshi Mashimo
    Applied Sciences.2019; 9(15): 2991.     CrossRef
  • Near-Infrared Fluorescent Activated Polymeric Probe for Imaging Intraluminal Colorectal Cancer Tumors
    Eva Kopansky-Groisman, Inga Kogan-Zviagin, Osnat Sella-Tavor, Mor Oron-Herman, Ayelet David
    Biomacromolecules.2019; 20(9): 3547.     CrossRef
  • Predictive factors for missed adenoma on repeat colonoscopy in patients with suboptimal bowel preparation on initial colonoscopy: A KASID multicenter study
    Ji Young Chang, Chang Mo Moon, Hyun Jung Lee, Hyo-Joon Yang, Yunho Jung, Sang Wook Kim, Sung-Ae Jung, Jeong-Sik Byeon, Frank T. Kolligs
    PLOS ONE.2018; 13(4): e0195709.     CrossRef
  • Cimetropium bromide does not improve polyp and adenoma detection during colonoscope withdrawal
    Peel Jung, Su B. Park, Hyung W. Kim, Dae H. Kang, Cheol W. Choi, Su J. Kim, Hyeong S. Nam, Dae G. Ryu, Joung B. Hong, Dong J. Kim
    Medicine.2018; 97(25): e11253.     CrossRef
  • Dielectric properties of colon polyps, cancer, and normal mucosa: Ex vivo measurements from 0.5 to 20 GHz
    Marta Guardiola, Santiago Buitrago, Glòria Fernández‐Esparrach, Joan M. O'Callaghan, Jordi Romeu, Miriam Cuatrecasas, Henry Córdova, Miguel Ángel González Ballester, Oscar Camara
    Medical Physics.2018; 45(8): 3768.     CrossRef
  • Quality is the key for emerging issues of population-based colonoscopy screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Intestinal Research.2018; 16(1): 48.     CrossRef
  • An Additional 30-s Observation of the Right-Sided Colon with Narrow Band Imaging Decreases Missed Polyps: A Pilot Study
    Naohisa Yoshida, Ken Inoue, Ritsu Yasuda, Ryohei Hirose, Osamu Dohi, Yuji Naito, Takaaki Murakami, Yutaka Inada, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Rafiz Abdul Rani, Yoshito Itoh
    Digestive Diseases and Sciences.2018; 63(12): 3457.     CrossRef
  • Quality is the Key for Emerging Issues of Population-Based Colonoscopy Screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Clinical Endoscopy.2018; 51(1): 50.     CrossRef
  • Additional Thirty Seconds Observation with Linked Color Imaging Improves Detection of Missed Polyps in the Right-Sided Colon
    Naohisa Yoshida, Yutaka Inada, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Ken Inoue, Osamu Dohi, Yuji Naito, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Eiichi Konishi, Yoshito Itoh
    Gastroenterology Research and Practice.2018; 2018: 1.     CrossRef
  • Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2)
    Jaeil Kim, Eun-ju Do, Helen Moinova, Sang Mun Bae, Ja Young Kang, Seung-Mo Hong, Stephen P. Fink, Jinmyoung Joo, Young-Ah Suh, Se Jin Jang, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Jaewon Choe, Suk-Kyun Yang, Sanfo
    Neoplasia.2017; 19(10): 805.     CrossRef
  • 10,785 View
  • 103 Download
  • 88 Web of Science
  • 75 Crossref
Close layer
Reviews
Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
Intest Res 2017;15(1):7-37.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.7
AbstractAbstract PDFPubReaderePub

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.

Citations

Citations to this article as recorded by  
  • The impact of gut microbiome enterotypes on ulcerative colitis: identifying key bacterial species and revealing species co-occurrence networks using machine learning
    Xuangao Wu, Ting Zhang, TianShun Zhang, Sunmin Park
    Gut Microbes.2024;[Epub]     CrossRef
  • Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report
    Jongbeom Shin, Ga Hyeon Baek, Boram Cha, Soo-Hyun Park, Jung-Hwan Lee, Jun-Seob Kim, Kye Sook Kwon
    Biomedicines.2024; 12(4): 800.     CrossRef
  • Anti‐inflammatory and anti‐hyperalgesic effects induced by an aqueous aged black garlic extract in rodent models of ulcerative colitis and colitis‐associated visceral pain
    Maria Loreta Libero, Elena Lucarini, Lucia Recinella, Clara Ciampi, Serena Veschi, Anna Piro, Annalisa Chiavaroli, Alessandra Acquaviva, Nilofar Nilofar, Giustino Orlando, Daniele Generali, Carla Ghelardini, Lorenzo di Cesare Mannelli, Antonio J. Montero‐
    Phytotherapy Research.2024; 38(8): 4177.     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
    Jiryeon Jang, Sehoon Jeong
    BioChip Journal.2023; 17(4): 403.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
    Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
    Therapeutic Advances in Gastroenterology.2023; 16: 175628482311541.     CrossRef
  • Low Serum Hepcidin Levels in Patients with Ulcerative Colitis – Implications for Treatment of Co-existent Iron-Deficiency Anemia
    Jagadish Ramasamy, Chinmai Jagadish, Abitha Sukumaran, Joe Varghese, Thenmozhi Mani, A. J. Joseph, Ebby George Simon, Molly Jacob
    Inflammation.2023; 46(6): 2209.     CrossRef
  • Screening for Chemical Characterization and Pharmacological Properties of Different Extracts from Nepeta italica
    Alessandra Acquaviva, Simonetta Cristina Di Simone, Nilofar, Abdelhakim Bouyahya, Gokhan Zengin, Lucia Recinella, Sheila Leone, Luigi Brunetti, Abdullahi Ibrahim Uba, Osman Guler, Maruf Balos, Ugur Cakilcioğlu, Luigi Menghini, Claudio Ferrante, Giustino
    Plants.2023; 12(15): 2785.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
    Digestive Diseases and Sciences.2022; 67(7): 2866.     CrossRef
  • Cytomegalovirus in ulcerative colitis: an evidence-based approach to diagnosis and treatment
    Anuraag Jena, Shubhra Mishra, Anupam Kumar Singh, Aravind Sekar, Vishal Sharma
    Expert Review of Gastroenterology & Hepatology.2022; 16(2): 109.     CrossRef
  • Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
    Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods
    Lin Zhang, Rui Mao, Chung Tai Lau, Wai Chak Chung, Jacky C. P. Chan, Feng Liang, Chenchen Zhao, Xuan Zhang, Zhaoxiang Bian
    Scientific Reports.2022;[Epub]     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
    The Korean Journal of Internal Medicine.2022; 37(5): 949.     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
    Seulji Kim, Seong-Joon Koh
    Intestinal Research.2022; 20(4): 389.     CrossRef
  • La escala control nutricional (CONUT): una herramienta prometedora para el cribado nutricional y como predictor de severidad en la colitis ulcerosa crónica idiopática
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México.2021; 86(2): 110.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature
    Kyung Muk Jeong, Ji Yun Seo, Anna Kim, Yoo Sang Baek, Hae Jun Song, Jiehyun Jeon
    Annals of Dermatology.2021; 33(1): 82.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Comparative Study of Anti-Inflammatory Effect on DSS-Induced Ulcerative Colitis Between Novel Glycyrrhiza Variety and Official Compendia
    Sa-Haeng Kang, Young-Jae Song, Yong-Deok Jeon, Dong-Keun Kim, Jeong-Hyang Park, Ju-Ryoun Soh, Jong-Hyun Lee, Christopher Kitalong, Wonnam Kim, Hyo-Jin An, Jae-Ki Chang, Jeonghoon Lee, Jong-Sik Jin
    Applied Sciences.2021; 11(4): 1545.     CrossRef
  • McN-A-343, a muscarinic agonist, reduces inflammation and oxidative stress in an experimental model of ulcerative colitis
    Diva de Aguiar Magalhães, Jalles Arruda Batista, Stefany Guimarães Sousa, Jayro dos Santos Ferreira, Lauanda da Rocha Rodrigues, Cynthia Maria Carvalho Pereira, José Victor do Nascimento Lima, Ieda Figueira de Albuquerque, Nayonara Lanara Sousa Dutra Beze
    Life Sciences.2021; 272: 119194.     CrossRef
  • Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
    Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2021; 15(2): 232.     CrossRef
  • The controlling nutritional status score: A promising tool for nutritional screening and predicting severity in ulcerative colitis patients
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México (English Edition).2021; 86(2): 110.     CrossRef
  • Comparison of outcomes of cyclosporine A and infliximab for steroid‐refractory acute severe ulcerative colitis
    Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Byong Duk Ye
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2463.     CrossRef
  • Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission
    Jongbeom Shin, Sung Min Kong, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2021; 15(3): 401.     CrossRef
  • The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
    Byong Duk Ye, Jae Hee Cheon, Ki Hwan Song, Joo Sung Kim, Young-Ho Kim, Hyuk Yoon, Kang-Moon Lee, Sang-Bum Kang, Byung Ik Jang, Jae Jun Park, Tae Oh Kim, Dae-Wook Lee, Chee Yoong Foo, Jeong Eun Shin, Dong Il Park
    Therapeutic Advances in Gastroenterology.2021; 14: 175628482110247.     CrossRef
  • Efficacy and safety of Etiasa for treatment of mild-to-moderate ulcerative colitis: A Meta-analysis
    Fang-Mei Ling, Fei-Nan Lu, Sheng-Nan Wang, Liang-Ru Zhu
    World Chinese Journal of Digestology.2021; 29(15): 880.     CrossRef
  • Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678 T , Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis
    Ryo Kutsuna, Tohru Miyoshi-Akiyama, Junko Tomida, Yoshiaki Kawamura, Steven R. Gill
    Microbiology Resource Announcements.2021;[Epub]     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study
    Eun Soo Kim, Hyun Seok Lee, Sung Kook Kim, Eun Young Kim, Byung Ik Jang, Kyeong Ok Kim, Chang Heon Yang, Yoo Jin Lee
    Scandinavian Journal of Gastroenterology.2020; 55(2): 163.     CrossRef
  • Multidirectional Pharma-Toxicological Study on Harpagophytum procumbens DC. ex Meisn.: An IBD-Focused Investigation
    Lucia Recinella, Annalisa Chiavaroli, Maurizio Ronci, Luigi Menghini, Luigi Brunetti, Sheila Leone, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Gokhan Zengin, Simonetta Di Simone, Maria Chiara Ciferri, Viviana di Giacomo, Amelia Ca
    Antioxidants.2020; 9(2): 168.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
    Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
    Intestinal Research.2019; 17(3): 349.     CrossRef
  • Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
    Ho Suk Kang, Ja-Seol Koo, Kang Moon Lee, Dae-Bum Kim, Ji Min Lee, Yoon Jae Kim, Hyuk Yoon, Hyun Joo Jang
    World Journal of Gastroenterology.2019; 25(8): 989.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Protective effects induced by alcoholic Phlomis fruticosa and Phlomis herba‐venti extracts in isolated rat colon: Focus on antioxidant, anti‐inflammatory, and antimicrobial activities in vitro
    Claudio Ferrante, Lucia Recinella, Maurizio Ronci, Giustino Orlando, Simonetta Di Simone, Luigi Brunetti, Annalisa Chiavaroli, Sheila Leone, Matteo Politi, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Sanda Vladimir‐Knežević, Luigi
    Phytotherapy Research.2019; 33(9): 2387.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
    Seong Ran Jeon
    Intestinal Research.2018; 16(2): 163.     CrossRef
  • Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
    Dae Bum Kim, Kang-Moon Lee, Sang Hyoung Park, You Sun Kim, Eun Soo Kim, Jun Lee, Sung-Ae Jung, Geom Seog Seo, Ji Min Lee
    Intestinal Research.2018; 16(2): 267.     CrossRef
  • Mesenchymal Stromal Cells in the Treatment of Perianal Fistulas in Crohn'S Disease
    Jesús Castro-Poceiro, Agnès Fernández-Clotet, Julián Panés
    Immunotherapy.2018; 10(14): 1203.     CrossRef
  • Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial
    Hyuk Yoon, Dong Ho Lee, Yong-Hyun Lee, Ju-Cheol Jeong, Soo Teik Lee, Myung-Gyu Choi, Seong Woo Jeon, Ki-Nam Shim, Gwang Ho Baik, Jae Gyu Kim, Jeong Seop Moon, In-Kyung Sung, Sang Kil Lee, Poong-Lyul Rhee, Hwoon-Yong Jung, Bong Eun Lee, Hyun Soo Kim, Sang
    Gut and Liver.2018; 12(5): 516.     CrossRef
  • Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
    Jihye Park, Jae Hee Cheon
    Intestinal Research.2017; 15(3): 263.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • 16,326 View
  • 204 Download
  • 60 Web of Science
  • 61 Crossref
Close layer
Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intest Res 2017;15(1):38-67.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.38
AbstractAbstract PDFSupplementary MaterialPubReaderePub

Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.

Citations

Citations to this article as recorded by  
  • Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn’s Disease: A Multicenter Observational Study
    Jihye Park, Jaeyoung Chun, Soo Jung Park, Jae Jun Park, Tae Il Kim, Hyuk Yoon, Jae Hee Cheon
    Digestive Diseases and Sciences.2024; 69(3): 901.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • Mobile monitoring system detects the disease activity pattern and shows the association with clinical outcomes in patients with newly diagnosed Crohn’s disease
    Yoo Jin Lee, Sang Gyu Kwak, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Yun Jin Chung, Byung Ik Jang, Kyeong Ok Kim, Jeongseok Kim, Hyeong Ho Jo, Eun Young Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Modern treatment of perianal fistulas following Crohn’s disease
    A.L. Bejanyan, A.A. Bumbazhai, K.N. Petrenko, A.A. Sumbaev, A.V. Matinyan, I.I. Eremin
    Regenerative biotechnologies, preventive, digital and predictive medicine.2024; 1(2): 49.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn’s Disease: A Study Based on the Korean National Database
    Gi Hyeon Seo, Sung Hoon Jung
    Journal of Clinical Medicine.2023; 12(6): 2397.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Can balloon-assisted enteroscopy predict disease outcomes in patients with small-bowel Crohn’s disease?
    Ji Eun Na, Sung Noh Hong, Ji Eun Kim, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
    Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim, Jae Hee Cheon
    Scientific Reports.2022;[Epub]     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
    Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
    Gut and Liver.2022; 16(6): 907.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn’s Disease Patients
    Pyeong Hwa Kim, Seo Hee Kim, Young Ah Cho, Hee Mang Yoon, Jin Seong Lee, Ah Young Jung, Seak Hee Oh, Dae Yeon Kim, Jung-Man Namgoong, Kyung Mo Kim
    Journal of Crohn's and Colitis.2021; 15(7): 1152.     CrossRef
  • Predictors of reoperation for perianal fistula in Crohn's disease
    Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung
    Journal of Digestive Diseases.2021; 22(6): 334.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease
    Min Seob Kwak, Jae Myung Cha, Ji Hyun Ahn, Min Kyu Chae, Sara Jeong, Hun Hee Lee
    Medicine.2020; 99(10): e18925.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effects of various genetic polymorphisms on thiopurine treatment‐associated outcomes for Korean patients with Crohn's disease
    Rihwa Choi, Mi‐Na Lee, Kyunga Kim, Sun‐Young Baek, Tae Jun Kim, Sung Noh Hong, Young‐Ho Kim, Soo‐Youn Lee
    British Journal of Clinical Pharmacology.2020; 86(11): 2302.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
    Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
    International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
  • Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
    Ji Young Chang, Jae Hee Cheon
    Digestive Diseases and Sciences.2019; 64(9): 2395.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Can Umbilical Cord Mesenchymal Stem Cells Treatment Be a Hope for Patients with Refractory Crohn's Disease?
    Younjoo Kim
    Gut and Liver.2018; 12(1): 5.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population‐based cohort study
    J. M. Bae, H. H. Lee, B.‐I. Lee, K.‐M. Lee, S. H. Eun, M.‐L. Cho, J. S. Kim, J. M. Park, Y.‐S. Cho, I. S. Lee, S. W. Kim, H. Choi, M.‐G. Choi
    Alimentary Pharmacology & Therapeutics.2018; 48(2): 196.     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
    Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280.     CrossRef
  • Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
    Jong Pil Im
    Intestinal Research.2017; 15(2): 147.     CrossRef
  • Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease
    Taku Kobayashi, Asahi Hishida, Hiroki Tanaka, Yoichiro Nuki, Shigeki Bamba, Akihiro Yamada, Toshimitsu Fujii, Shinichiro Shinzaki, Yoko Yokoyama, Atsushi Yoshida, Keiji Ozeki, Shinya Ashizuka, Noriko Kamata, Sohachi Nanjo, Kazuki Kakimoto, Misaki Nakamura
    Inflammatory Bowel Diseases.2017; 23(12): 2245.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
    Dai Jung, Sunghee Lee, Insook Jeong, Seak Hee Oh, Kyung Mo Kim
    Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 236.     CrossRef
  • 11,148 View
  • 159 Download
  • 39 Web of Science
  • 43 Crossref
Close layer
Original Articles
Determining the optimal surveillance interval after a colonoscopic polypectomy for the Korean population?
Jung Lok Lee, Jae Myung Cha, Hye Min Lee, Jung Won Jeon, Min Seob Kwak, Jin Young Yoon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee, Dong Il Park
Intest Res 2017;15(1):109-117.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.109
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Western surveillance strategies cannot be directly adapted to the Korean population. The aim of this study was to estimate the risk of metachronous neoplasia and the optimal surveillance interval in the Korean population.

Methods

Clinical and pathological data from index colonoscopy performed between June 2006 and July 2008 and who had surveillance colonoscopies up to May 2015 were compared between low- and high-risk adenoma (LRA and HRA) groups. The 3- and 5-year cumulative risk of metachronous colorectal neoplasia in both groups were compared.

Results

Among 895 eligible patients, surveillance colonoscopy was performed in 399 (44.6%). Most (83.3%) patients with LRA had a surveillance colonoscopy within 5 years and 70.2% of patients with HRA had a surveillance colonoscopy within 3 years. The cumulative risk of metachronous advanced adenoma was 3.2% within 5 years in the LRA group and only 1.7% within 3 years in the HRA group. The risk of metachronous neoplasia was similar between the surveillance interval of <5 and ≥5 years in the LRA group; however, it was slightly higher at surveillance interval of ≥3 than <3 years in the HRA group (9.4% vs. 2.4%). In multivariate analysis, age and the ≥3-year surveillance interval were significant independent risk factors for metachronous advanced adenoma (P=0.024 and P=0.030, respectively).

Conclusions

Patients had a surveillance colonoscopy before the recommended guidelines despite a low risk of metachronous neoplasia. However, the risk of metachronous advanced adenoma was increased in elderly patients and those with a ≥3-year surveillance interval.

Citations

Citations to this article as recorded by  
  • Risk of developing metachronous colorectal neoplasia after the resection of proximal versus distal adenomas
    Yoon Suk Jung, Nam Hee Kim, Youngwoo Kim, Dong Il Park
    Digestive and Liver Disease.2022; 54(4): 537.     CrossRef
  • Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study
    Amanda J. Cross, Emma C. Robbins, Kevin Pack, Iain Stenson, Matthew D. Rutter, Andrew M. Veitch, Brian P. Saunders, Stephen W. Duffy, Kate Wooldrage
    Endoscopy.2022; 54(10): 948.     CrossRef
  • Comparison of Risk of Metachronous Advanced Colorectal Neoplasia in Patients with Sporadic Adenomas Aged < 50 Versus ≥ 50 years: A Systematic Review and Meta-Analysis
    Yoon Suk Jung, Jung Ho Park, Chan Hyuk Park
    Journal of Personalized Medicine.2021; 11(2): 120.     CrossRef
  • British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines
    Matthew D Rutter, James East, Colin J Rees, Neil Cripps, James Docherty, Sunil Dolwani, Philip V Kaye, Kevin J Monahan, Marco R Novelli, Andrew Plumb, Brian P Saunders, Siwan Thomas-Gibson, Damian J M Tolan, Sophie Whyte, Stewart Bonnington, Alison Scope,
    Gut.2020; 69(2): 201.     CrossRef
  • Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer
    Eun Ran Kim, Hyuk Nam Kwon, Hoonsik Nam, Jae J. Kim, Sunghyouk Park, Young-Ho Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • A Comparison of the Cumulative Incidences of Metachronous Colorectal Adenoma and Cancer According to the Initial FindingsAmong Colonoscopically Followed-up Patients
    Seiji Kimura, Masanori Tanaka, Shinsaku Fukuda
    Nippon Daicho Komonbyo Gakkai Zasshi.2019; 72(6): 395.     CrossRef
  • Impact of obesity and metabolic abnormalities on the risk of metachronous colorectal neoplasia after polypectomy in men
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Journal of Gastroenterology and Hepatology.2019; 34(9): 1504.     CrossRef
  • Risk of developing metachronous advanced colorectal neoplasia after colonoscopic polypectomy in patients aged 30 to 39 and 40 to 49 years
    Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
    Gastrointestinal Endoscopy.2018; 88(4): 715.     CrossRef
  • Quality is the Key for Emerging Issues of Population-Based Colonoscopy Screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Clinical Endoscopy.2018; 51(1): 50.     CrossRef
  • Histologic discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimens of colorectal polyp in actual clinical practice
    Moon Joo Hwang, Kyeong Ok Kim, A Lim Kim, Si Hyung Lee, Byung Ik Jang, Tae Nyeun Kim
    Intestinal Research.2018; 16(3): 475.     CrossRef
  • Quality is the key for emerging issues of population-based colonoscopy screening
    Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
    Intestinal Research.2018; 16(1): 48.     CrossRef
  • 5,903 View
  • 59 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Comparison of the efficacy of disinfectants in automated endoscope reprocessors for colonoscopes: tertiary amine compound (Sencron2®) versus ortho-phthalaldehyde (Cidex®OPA)
Hyun Il Seo, Dae Sung Lee, Eun Mi Yoon, Min-Jung Kwon, Hyosoon Park, Yoon Suk Jung, Jung Ho Park, Chong Il Sohn, Dong Il Park
Intest Res 2016;14(2):178-182.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.178
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To prevent the transmission of pathogens by endoscopes, following established reprocessing guidelines is critical. An ideal reprocessing step is simple, fast, and inexpensive. Here, we evaluated and compared the efficacy and safety of two disinfectants, a tertiary amine compound (TAC) and ortho-phthalaldehyde (OPA).

Methods

A total of 100 colonoscopes were randomly reprocessed using two same automated endoscope reprocessors, according to disinfectant. The exposure time was 10 minutes for 0.55% OPA (Cidex® OPA, Johnson & Johnson) and 5 minutes for 4% TAC (Sencron2®, Bab Gencel Pharma & Chemical Ind. Co.). Three culture samples were obtained from each colonoscope after reprocessing.

Results

A total of nine samples were positive among the 300 culture samples. The positive culture rate was not statistically different between the two groups (4% for OPA and 2% for TAC, P=0.501). There were no incidents related to safety during the study period.

Conclusions

TAC was non-inferior in terms of reprocessing efficacy to OPA and was safe to use. Therefore, TAC seems to be a good alternative disinfectant with a relatively short exposure time and is also less expensive than OPA.

Citations

Citations to this article as recorded by  
  • Synthesis, Characterization and Investigation of Antimicrobial Activity of Orthophtaldehyde Nanoflowers
    Gülten CAN SEZGİN, Nilay ILDİZ
    Middle Black Sea Journal of Health Science.2023; 9(2): 245.     CrossRef
  • A Manufacturer and User Facility Device Experience Analysis of Upper Aerodigestive Endoscopy Contamination: Is Flexible Laryngoscopy Different?
    Roy Jiang, David A. Kasle, Faisal Alzahrani, Nikita Kohli, Michael Z. Lerner
    The Laryngoscope.2021; 131(3): 598.     CrossRef
  • Electrochemical and Spectrometric Study of Reactivity of Orthophthalaldehyde with Hydroxylamine: Mechanistic Considerations
    Joël Donkeng‐Dazie, Jiří Urban, Jiří Ludvík
    ChemistrySelect.2021; 6(20): 4881.     CrossRef
  • Reactivity of orthophthalaldehyde with aliphatic, alicyclic and aromatic primary diamines: Electrochemical study and mechanistic considerations
    Joël Donkeng Dazie, Alan Liška, Jiří Urban, Jiří Ludvík
    Journal of Electroanalytical Chemistry.2018; 821: 131.     CrossRef
  • Efficacy of Peracetic Acid (EndoPA®) for Disinfection of Endoscopes
    Ji Min Lee, Kang-Moon Lee, Dae Bum Kim, Se Eun Go, Sungwoo Ko, Yoongoo Kang, Solim Hong
    The Korean Journal of Gastroenterology.2018; 71(6): 319.     CrossRef
  • Planarity of substituted pyrrole and furan rings in (3R*, 1′S*, 3′R*)-3-(1′-tert-butylamino-1′H, 3′ H-benzo[c]furan-3′-yl)-2-tert-butyl-2,3-dihydro-1H-benzo[c]pyrrol-1-one
    Joel Donkeng Dazie, Alan Liška, Jiří Ludvík, Jan Fábry, Michal Dušek, Václav Eigner
    Zeitschrift für Kristallographie - Crystalline Materials.2017; 232(6): 441.     CrossRef
  • 6,241 View
  • 49 Download
  • 3 Web of Science
  • 6 Crossref
Close layer
The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease
Dae Sung Lee, Ki Bae Bang, Ji Yeon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Young Choi, Dong Il Park
Intest Res 2016;14(1):43-49.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.43
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Quality of life is closely related to anemia in patients with inflammatory bowel disease (IBD). Several studies have reported on anemia in patients with IBD in Western countries. This study investigated the prevalence and clinical characteristics of anemia in Korean patients with IBD.

Methods

We reviewed the medical records of 92 patients with ulcerative colitis (UC) and 76 patients with Crohn's disease (CD) who were followed regularly at a single tertiary medical center in Korea between January 2003 and December 2012. Hemoglobin (Hb) thresholds used to define anemia were <13.0 g/dL in men and <12.0 g/dL in women according to the World Health Organization criteria. We chose the lowest Hb level in each year as a representative value because Hb levels changed at each examination and anemia was associated with disease deterioration. The relationship between clinical variables and lowest Hb level was assessed.

Results

The prevalence of anemia was 36.3% in patients with UC and 41.6% in patients with CD. Anemia in patients with CD was associated with hospital admission, 5-aminosalicylate (5-ASA) and infliximab treatment in men. Anemia in patients with UC was associated with hospital admission, oral steroid use, thiopurine and infliximab treatment in men.

Conclusions

The prevalence of anemia in Korean patients with IBD was comparable to that of patients in Western countries. Anemia was associated with male patients with CD who were admitted to the hospital and received medications including 5-ASA and infliximab, and men with UC who were admitted to the hospital and received medications including oral steroids, thiopurine and infliximab.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and north-south differences of inflammatory bowel disease in China: A cross-sectional study and meta-analysis
    Qi Liang, Bo Qu, Chunye Li, Yue Hu, Chunyi Yang, Tingting Yang, Yuzhu Di, Hui Li
    Frigid Zone Medicine.2024; 4(1): 23.     CrossRef
  • Clinical and Laboratory Characteristics of Anaemia in Hospitalized Patients with Inflammatory Bowel Disease
    Małgorzata Woźniak, Anna Borkowska, Marta Jastrzębska, Marcin Sochal, Ewa Małecka-Wojciesko, Renata Talar-Wojnarowska
    Journal of Clinical Medicine.2023; 12(7): 2447.     CrossRef
  • Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
    Natália Souza Nunes Siqueira, Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Marina Moreira de Castro, Alan Sidnei Corrêa Martins, Dante Orsetti Silva Araújo, Luis Eduardo Miani Gomes, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, Raquel Fra
    World Journal of Clinical Cases.2023; 11(12): 2740.     CrossRef
  • ANEMIA AND IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A REFERRAL CENTER IN BRAZIL: PREVALENCE AND RISK FACTORS
    Rogério Serafim PARRA, Marley Ribeiro FEITOSA, Sandro da Costa FERREIRA, José Joaquim Ribeiro da ROCHA, Luiz Ernesto de Almeida TRONCON, Omar FÉRES
    Arquivos de Gastroenterologia.2020; 57(3): 272.     CrossRef
  • Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease
    Göksel Bengi, Hatice Keyvan, Seda Bayrak Durmaz, Hale Akpınar
    World Journal of Gastroenterology.2018; 24(36): 4186.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Should asymptomatic young men with iron deficiency anemia necessarily undergo endoscopy?
    Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
    The Korean Journal of Internal Medicine.2018; 33(6): 1084.     CrossRef
  • Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients
    Alfredo J. Lucendo, Ángel Arias, Óscar Roncero, Daniel Hervías, Cristina Verdejo, Carmen Naveas-Polo, Abdelmouneim Bouhmidi, Rufo Lorente, Luis Miguel Alcázar, Irina Salueña, Julio A. García-Quiñones, María Jesús Carrillo-Ramos
    Digestive and Liver Disease.2017; 49(4): 405.     CrossRef
  • 5,129 View
  • 63 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Review
Current status of biosimilars in the treatment of inflammatory bowel diseases
Dong Il Park
Intest Res 2016;14(1):15-20.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.15
AbstractAbstract PDFPubReaderePub

Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.

Citations

Citations to this article as recorded by  
  • Drugs with the highest drug expenditure in the Republic of Serbia
    Boris Milijašević, Anđela Milak, Milan Ubavić, Dane Krtinić, Gorana Nedin-Ranković, Hristina Jovanović, Hristina Trajković, Dragana Milijašević, Radmila Popović, Nemanja Todorović, Mladena Lalić-Popović, Nikola Vukosav, Branko Baljak, Milan Tošić, Radmila
    Hospital Pharmacology - International Multidisciplinary Journal.2023; 10(2): 1301.     CrossRef
  • International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States
    Yun‐Kyoung Song, Nayoung Han, Gilbert J. Burckart, Jung Mi Oh
    Clinical Pharmacology & Therapeutics.2020; 107(3): 530.     CrossRef
  • Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
    Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus
    Intestinal Research.2020; 18(1): 34.     CrossRef
  • Characteristics of biological therapy in pediatric patients with Crohn’s disease
    Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres
    Expert Opinion on Biological Therapy.2019; 19(3): 181.     CrossRef
  • Use of Biosimilars in Pediatric Inflammatory Bowel Disease
    Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto,
    Journal of Pediatric Gastroenterology and Nutrition.2019; 68(1): 144.     CrossRef
  • Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review
    Laura Martelli, Laurent Peyrin-Biroulet
    Current Medicinal Chemistry.2019; 26(2): 270.     CrossRef
  • Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
    Intestinal Research.2019; 17(4): 504.     CrossRef
  • Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
    Soo-Kyung Park, Won Moon, Eun Soo Kim, Sang Hyun Park, Dong Il Park
    The Korean Journal of Gastroenterology.2019; 74(6): 333.     CrossRef
  • The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
    G.S. Fernandes, C. Sternberg, G. Lopes, R. Chammas, M.A.C. Gifoni, R.A. Gil, D.V. Araujo
    Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
  • Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
    Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood
    Intestinal Research.2018; 16(1): 83.     CrossRef
  • Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence
    Sean McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan
    Expert Review of Clinical Pharmacology.2017; 10(4): 391.     CrossRef
  • Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
    András Inotai, Christiaan P.J Prins, Marcell Csanádi, Dinko Vitezic, Catalin Codreanu, Zoltán Kaló
    Expert Opinion on Biological Therapy.2017; 17(8): 915.     CrossRef
  • Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model
    Seung Kak Shin, Jae Hee Cho, Eui Joo Kim, Eun-Kyung Kim, Dong Kyun Park, Kwang An Kwon, Jun-Won Chung, Kyoung Oh Kim, Yoon Jae Kim
    World Journal of Gastroenterology.2017; 23(25): 4559.     CrossRef
  • Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease
    Sang Hyoung Park, Satimai Aniwan, Edward V Loftus
    Current Opinion in Pharmacology.2017; 37: 65.     CrossRef
  • Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
    Seong Ran Jeon
    Gut and Liver.2017; 11(2): 171.     CrossRef
  • 4,954 View
  • 46 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Case Report
Perianal Abscess and Proctitis by Klebsiella pneumoniae
Woo Shin Jeong, Sung Youn Choi, Eun Haeng Jeong, Ki Bae Bang, Seung Sik Park, Dae Sung Lee, Dong Il Park, Yoon Suk Jung
Intest Res 2015;13(1):85-89.   Published online January 29, 2015
DOI: https://doi.org/10.5217/ir.2015.13.1.85
AbstractAbstract PDFPubReader

Klebsiella pneumoniae (K. pneumoniae) can at times cause invasive infections, especially in patients with diabetes mellitus and a history of alcohol abuse. A 61-year-old man with diabetes mellitus and a history of alcohol abuse presented with abdominal and anal pain for two weeks. After admission, he underwent sigmoidoscopy, which revealed multiple ulcerations with yellowish exudate in the rectum and sigmoid colon. The patient was treated with ciprofloxacin and metronidazole. After one week, follow up sigmoidoscopy was performed owing to sustained fever and diarrhea. The lesions were aggravated and seemed webbed in appearance because of damage to the rectal mucosa. Abdominal computed tomography and rectal magnetic resonance imaging were performed, and showed a perianal and perirectal abscess. The patient underwent laparoscopic sigmoid colostomy and perirectal abscess incision and drainage. Extended-spectrum beta-lactamase-producing K. pneumoniae was identified in pus culture. The antibiotics were switched to ertapenem. He improved after surgery and was discharged. K. pneumoniae can cause rapid invasive infection in patients with diabetes and a history of alcohol abuse. We report the first rare case of proctitis and perianal abscess caused by invasive K. pneumoniae infection.

Citations

Citations to this article as recorded by  
  • Microbiota in adult perianal abscess revealed by metagenomic next-generation sequencing
    Jian-Chen Hong, Jian-Sheng Chen, Zai-Jie Jiang, Zhi-Chuan Chen, Ning Ruan, Xiang-Ping Yao, Rosemary C. She
    Microbiology Spectrum.2024;[Epub]     CrossRef
  • An Unusual Case of Proctitis and Rectal Abscess due to Irritants byArtemisia asiaticaSmoke (Ssukjwahun)
    Seunghyup Kim, You Sun Kim, Seo Hyun Kim, Dong Hoon Lee, Se Jun Park, Seo Young Yun, Dae Young Kim, Jeonghun Lee, Jeong Seop Moon
    The Korean Journal of Gastroenterology.2016; 67(4): 212.     CrossRef
  • 8,690 View
  • 50 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Original Articles
Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Park
Intest Res 2014;12(4):281-286.   Published online October 27, 2014
DOI: https://doi.org/10.5217/ir.2014.12.4.281
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Several recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.

Methods

Patients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.

Results

Of the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P<0.001) and IFX use (P<0.001) after diagnosis were significantly higher in the second group, there were no significant differences in cumulative probabilities of operation (P=0.905) or reoperation (P=0.418) between two groups.

Conclusions

The early use of IFX did not reduce CD-related surgery requirements in Korean patients with CD. These study results suggest that the early use of IFX may have little impact on the clinical outcome of CD in Korean patients in the setting of a conventional step-up algorithm.

Citations

Citations to this article as recorded by  
  • Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
    Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
    Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
    Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao
    Heliyon.2023; 9(9): e19609.     CrossRef
  • Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
    Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question
    Ashish Srinivasan, Daniel R. van Langenberg
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 718.     CrossRef
  • Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
    Cong-Qiu Chu
    Chinese Medical Journal.2021; 134(21): 2525.     CrossRef
  • A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
    Kenechukwu O Chudy-Onwugaje, Kaci E Christian, Francis A Farraye, Raymond K Cross
    Inflammatory Bowel Diseases.2019; 25(5): 820.     CrossRef
  • Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
    Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
    Middle East Journal of Digestive Diseases.2019; 12(1): 12.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
    Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
    Gut and Liver.2018; 12(5): 544.     CrossRef
  • Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
    Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk-Kyun Yang
    Journal of Korean Medical Science.2017; 32(1): 85.     CrossRef
  • Fecal microbiota transplantation for refractory Crohn's disease
    Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
    Intestinal Research.2017; 15(2): 244.     CrossRef
  • Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
    Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
    Digestive Diseases and Sciences.2016; 61(7): 2060.     CrossRef
  • Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
    Gut and Liver.2016;[Epub]     CrossRef
  • The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease Patients
    Kyeong Ok Kim
    Gut and Liver.2016; 10(4): 487.     CrossRef
  • Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
    Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
    Intestinal Research.2016; 14(1): 30.     CrossRef
  • Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease
    Stanislaus Argeny, Anton Stift, Martina Mittlböck, Amy C. Lord, Svenja Maschke, Mathias Schneeweiß, Stefan Riss
    International Journal of Surgery.2016; 33: 182.     CrossRef
  • The clinical usefulness of a web-based messaging system between patients with Crohn disease and their physicians
    Da Eun Jeong, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Jin Tae Jung, Seong Woo Jeon, Hyun Seok Lee, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho
    Medicine.2016; 95(26): e4028.     CrossRef
  • The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
    Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
    BMC Gastroenterology.2015;[Epub]     CrossRef
  • Management of Anemia in Patients with Inflammatory Bowel Disease
    Kyeong Ok Kim
    The Korean Journal of Gastroenterology.2015; 65(3): 145.     CrossRef
  • Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
    Byong Duk Ye
    Intestinal Research.2014; 12(4): 263.     CrossRef
  • 5,084 View
  • 56 Download
  • 20 Web of Science
  • 21 Crossref
Close layer
The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
Hyun Il Seo, Dong Il Park, Tae Oh Kim, You Sun Kim, Suck-Ho Lee, Ji Won Kim, Jae Hak Kim, Jeong Eun Shin
Intest Res 2014;12(3):214-220.   Published online July 25, 2014
DOI: https://doi.org/10.5217/ir.2014.12.3.214
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea.

Methods

From 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline.

Results

Twenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5; P=0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin.

Conclusions

If there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.

Citations

Citations to this article as recorded by  
  • Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
    Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
    Middle East Journal of Digestive Diseases.2019; 12(1): 12.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea
    Hyungil Seo, Kiju Chang, Sun-Ho Lee, Eun-Mi Song, Gwang-Un Kim, Myeongsook Seo, Ho-Su Lee, Sung-Wook Hwang, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Scandinavian Journal of Gastroenterology.2017; 52(8): 857.     CrossRef
  • Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin
    Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts
    European Journal of Gastroenterology & Hepatology.2016; 28(4): 369.     CrossRef
  • Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Yoon Suk Jung, Dong Il Park, Young Ho Kim, Ji Hyun Lee, Pyoung Ju Seo, Jae Hee Cheon, Hyoun Woo Kang, Ji Won Kim
    Journal of Gastroenterology and Hepatology.2015; 30(12): 1705.     CrossRef
  • Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
    Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
    Intestinal Research.2015; 13(3): 213.     CrossRef
  • Circulating Ghrelin Levels and Obestatin/Ghrelin Ratio as a Marker of Activity in Ulcerative Colitis
    Ja Young Jung, Ji Bong Jeong, Ji Won Kim, Su Hwan Kim, Seong-Joon Koh, Byeong Gwan Kim, Kook Lae Lee
    Intestinal Research.2015; 13(1): 68.     CrossRef
  • How to Write Bibliographies for Citing Domestic Academic Resources
    Hyun Jung Yi
    The Korean Journal of Gastroenterology.2015; 65(1): 70.     CrossRef
  • Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?
    Chang Soo Eun, Dong Soo Han
    Gut and Liver.2015;[Epub]     CrossRef
  • Current and Emerging Biologics for Ulcerative Colitis
    Sung Chul Park, Yoon Tae Jeen
    Gut and Liver.2015; 9(1): 18.     CrossRef
  • 4,904 View
  • 36 Download
  • 8 Web of Science
  • 10 Crossref
Close layer
Letters to the Editor
Author's Reply
Dong Il Park
Intest Res 2014;12(2):171-171.   Published online April 29, 2014
DOI: https://doi.org/10.5217/ir.2014.12.2.171
PDFPubReader
  • 9,616 View
  • 38 Download
Close layer
Original Articles
Prevalence, Clinicopathologic Characteristics, and Predictors of Interval Colorectal Cancers in Korean Population
Chang Joon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Shin Yeong Lee, Hwa Mok Kim, Ki Bae Bang, Dae Sung Lee, Dong Il Park
Intest Res 2013;11(3):178-183.   Published online July 30, 2013
DOI: https://doi.org/10.5217/ir.2013.11.3.178
AbstractAbstract PDF
Background/Aims
A subset of patients may develop colorectal cancer after a colonoscopy that was negative for carcinoma. These missed or de novo developed lesions were termed as interval cancers. Many studies regarding interval cancer have been conducted in Western countries, whereas very limited data are available in Asian populations. Therefore, the purpose of this study was to investigate prevalence, clinicopathologic features, and predictors of interval colorectal cancers in the Korean population. Methods: Interval cancer was defined as a cancer that is diagnosed within 5 years of a negative colonoscopy result. Among the patients who were diagnosed colorectal cancers at Kangbuk Samsung Hospital from January 2007 to April 2012, clinicopathologic characteristics of interval cancers were compared with those of sporadic cancers. Results: Among the 785 patients, 482 responded to telephone calls. Of these, 30 (6.2%) developed interval cancers. Finally, 28 patients who had interval cancers were compared with 415 patients who had sporadic cancers. Interval cancer group was significantly younger and more frequent in the right side colon than sporadic cancer group. There was no differences in sex, tumor size, differentiation, and staging between two groups. In multivariate analysis, young age and right side colon cancer were independent factors associated with an interval cancer. Conclusions: A significant proportion of Korean patients developed interval colorectal cancer, especially at the young age and in the proximal colon. (Intest Res 2013;11:178-183)

Citations

Citations to this article as recorded by  
  • Clinical and endoscopic characteristics of sessile serrated lesions with dysplasia/carcinoma
    Peel Jung, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam, Dae Gon Ryu, Dong Hoon Shin, Joo Young Na, Mi Sook Yun
    The Korean Journal of Internal Medicine.2023; 38(3): 349.     CrossRef
  • Post-colonoscopy Colorectal Cancer: Causes and Prevention of Interval Colorectal Cancer
    Jong Yoon Lee, Jong Hoon Lee
    The Korean Journal of Gastroenterology.2020; 75(6): 314.     CrossRef
  • Frequency and Characteristics of Interval Colorectal Cancer in Actual Clinical Practice: A KASID Multicenter Study
    Kyeong Ok Kim, Kyu Chan Huh, Sung Pil Hong, Won Hee Kim, Hyuk Yoon, Sang Wook Kim, Yeon Soo Kim, Jong Ha Park, Jun Lee, Bum Jae Lee, Young Sook Park
    Gut and Liver.2018; 12(5): 537.     CrossRef
  • Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2)
    Jaeil Kim, Eun-ju Do, Helen Moinova, Sang Mun Bae, Ja Young Kang, Seung-Mo Hong, Stephen P. Fink, Jinmyoung Joo, Young-Ah Suh, Se Jin Jang, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Jaewon Choe, Suk-Kyun Yang, Sanfo
    Neoplasia.2017; 19(10): 805.     CrossRef
  • External Validation of the Endoscopic Features of Sessile Serrated Adenomas in Expert and Trainee Colonoscopists
    Hyo-Joon Yang, Jeong In Lee, Soo-Kyung Park, Yoon Suk Jung, Jin Hee Sohn, Kyu Yong Choi, Dong Il Park
    Clinical Endoscopy.2017; 50(3): 279.     CrossRef
  • Comparative Study on Bowel Preparation Efficacy of Ascorbic Acid Containing Polyethylene Glycol by Adding Either Simethicone or 1 L of Water in Health Medical Examination Patients: A Prospective Randomized Controlled Study
    Se Hwan Yeo, Jae Hoon Kwak, Yeo Un Kim, Tae Ho Kwon, Jeong Bae Park, Jun Hyung Park, Yong Kook Lee, Yun Jeong Lim, Chang Heon Yang
    The Korean Journal of Gastroenterology.2016; 67(4): 189.     CrossRef
  • Microsatellite Instability Status of Interval Colorectal Cancers in a Korean Population
    Kil Woo Lee, Soo-Kyung Park, Hyo-Joon Yang, Yoon Suk Jung, Kyu Yong Choi, Kyung Eun Kim, Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Ho-Kyung Chun, Dong Il Park
    Gut and Liver.2016; 10(5): 781.     CrossRef
  • Characteristics of and risk factors for colorectal neoplasms in young adults in a screening population
    Seung Eun Lee, Hee Bum Jo, Won Gun Kwack, Yun Jin Jeong, Yeo-Jin Yoon, Hyoun Woo Kang
    World Journal of Gastroenterology.2016; 22(10): 2981.     CrossRef
  • Randomized Controlled Trial of Sodium Phosphate Tablets versus 2 L Polyethylene Glycol Solution for Bowel Cleansing prior to Colonoscopy
    Yun Ho Lee, Seong Yeon Jeong, You Sun Kim, Hye Jin Jung, Min Jung Kwon, Cheol Hun Kwak, Song I Bae, Jeong Seop Moon, Ji Won Kim, Su Hwan Kim, Kook Lae Lee
    The Korean Journal of Gastroenterology.2015; 65(1): 27.     CrossRef
  • The Risk of Metachronous Advanced Colorectal Neoplasia Rises in Parallel with an Increasing Number of High-Risk Findings at Baseline
    Seung Min Lee, Jeong Hwan Kim, In Kyung Sung, Sung Noh Hong
    Gut and Liver.2015; 9(6): 741.     CrossRef
  • Rapidly Growing Interval Colon Cancer
    Jae Hyun Kim, Moo In Park
    The Korean Journal of Gastroenterology.2015; 65(5): 326.     CrossRef
  • Colonoscopy Quality is the Answer for the Emerging Issue of Interval Cancer
    Jae Myung Cha
    Intestinal Research.2014; 12(2): 110.     CrossRef
  • Interval Cancers after a Negative Colonoscopy Finding in a Korean Population: A Small Step for Gastroenterologists but One Giant Leap for Koreans
    Jae Myung Cha
    Intestinal Research.2014; 12(2): 169.     CrossRef
  • Author's Reply
    Dong Il Park
    Intestinal Research.2014; 12(2): 171.     CrossRef
  • Development and Predictor of Interval Colorectal Cancer
    Tae-Oh Kim
    Intestinal Research.2013; 11(3): 153.     CrossRef
  • What Matters in Colonoscopy?
    Hyun Shig Kim
    Annals of Coloproctology.2013; 29(6): 223.     CrossRef
  • 2,765 View
  • 43 Download
  • 16 Crossref
Close layer
Exposure to Diagnostic Radiation in Patients with Inflammatory Bowel Disease: A Single Center Study
Jae Wan Lim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Dong Il Park
Intest Res 2013;11(2):107-112.   Published online April 30, 2013
DOI: https://doi.org/10.5217/ir.2013.11.2.107
AbstractAbstract PDF
Background/Aims
Western studies recently reported that patients with inflammatory bowel disease (IBD) are exposed to diagnostic radiation at potentially harmful levels. There is little research, however, on exposure to diagnostic radiation in patients with IBD in Asian areas. The present study assessed cumulative radiation exposure dose in patients with IBD who were treated at a single-tertiary medical center in Korea and analyzed the factors that increased the exposure dose. Methods: Retrospective investigation was performed of the medical records of the patients who were followed up for 1 year or more in a period from January 2003 through November 2011 at Kangbuk Samsung Hospital. Results: Included in the study were 202 patients with IBD: 80 (39.6%) had Crohn's disease (CD) and 122 (60.4%) had ulcerative colitis (UC). The mean follow-up period was 4.2±2.5 years for CD and 4.3±1.4 years for UC. The mean culmulative effective dose (CED) for CD and UC were 39.7 and 11.0 mSv respectively (P<0.001). In CD, factors associated with increased CED were surgery, history of intravenous steroid treatment, and structuring or penetrating disease. Conclusions: A substantial proportion of IBD patients, especially CD patients, were exposed to significantly harmful amounts of diagnostic radiation, mainly due to computed tomography examination. Efforts should be made to reduced diagnostic medical radiation, especially in patients at risk for increased radiation exposure. (Intest Res 2013;11:107-112)
  • 2,308 View
  • 13 Download
Close layer
The Effect of Transfection of RET9 and RET51 on Apoptosis in SW48 and RKO Colon Cancer Cells
Hyun Il Seo, Dong Il Park
Intest Res 2013;11(1):28-33.   Published online January 31, 2013
DOI: https://doi.org/10.5217/ir.2013.11.1.28
AbstractAbstract PDF
Background/Aims
Dependent receptor can transmit both positive signal: proliferation, differentiation or migration; and negative signal: apoptosis. It depends on the presence of its ligand. This study was performed to determine the effects of transfection of dependent receptors in human colon cancer cell lines. Methods: Two dependent receptors (rearranged during transfection [RET]9 and RET51) were transfected into three human colon cancer cell lines: SW48, RKO and V400. Then, half of them were treated with glial cell line-derived neurotrophic factor (GDNF). Using ELISA and caspase assay, apoptosis was measured. Dose-response relation between GDNF and apoptosis was also analyzed. A pcDNA was used as an empty vector. Results: After transfection of RET51, apoptosis was increased in SW48 (70% with ELISA and 119% with caspase assay) and RKO (255% with ELISA and 106% with caspase assay) cell lines when compared with the pcDNA group. V400 cell line did not show increased apoptosis. Transfection of RET9 did not induce apoptosis in all of the three human colon cancer cell lines. Treatment with GDNF 12 hours after transfection of RET51 decreased apoptosis in SW48 (66% with ELISA and 60% with caspase assay) and RKO (39% with ELISA and 57% with caspase assay) when compared with the cell lines transfected with RET51 only. Apoptosis was down-regulated with increasing concentration of GDNF in RKO cell line. Conclusions: This study showed that the apoptosis of human colon cancer cell line can be controlled by manipulating the dependent receptors and its ligands. We present the possibility of therapeutic method using dependent receptor in colon cancer. (Intest Res 2013;11:28-33)
  • 2,634 View
  • 28 Download
Close layer
Review
Variable Clinical Classifications and Diagnostic Coding Systems of Colorectal Neuroendocrine Tumor
Byung Chang Kim, Cheol Hee Park, Tae Il Kim, Suck-Ho Lee, Jin-Oh Kim, Hyun Soo Kim, Dong-Hoon Yang, Bora Keum, Sung Pil Hong, Seong-Eun Kim, Hyun Gun Kim, Jeong Eun Shin, Jae Myung Cha, Young Eun Joo, Dong Il Park, Hwang Choi, Kyu Chan Huh, Seung-Jae Myung, Dong Kyung Chang, Seun Ja Park
Intest Res 2013;11(1):14-22.   Published online January 31, 2013
DOI: https://doi.org/10.5217/ir.2013.11.1.14
AbstractAbstract PDF
The incidence of colorectal carcinoid tumor is recently increasing as screening colonoscopy increased. Traditional carcinoid tumor had been known as low grade, malignant neuroendocrine cell orign tumor. In 2000, World Health Organization (WHO) suggested that carcinoid was called well-differentiated neuroendocrine tumor (NET). It recently updated in 2010 by WHO; according to the differentiation and malignant potential, NET classified with NET Grade 1, Grade 2, and neuroendocrine carcinoma. They suggested that NET had malignant potential in accordance with histopathologic characteristics. Therefore, WHO recommended the behavior code of NET as malignant. However, European Neuroendocrine Tumor Society (ENETS) proposed the behavior of NET to four grades based on the histopathologic features; benign, benign or low grade malignant, low grade malignant, and high grade malignant. Also, American Joint Committee on Cancer (AJCC) suggested that topography codes of NET were defined as malignant. Korean Standard Classification of Diseases (KCD) described the different codings of carcinoid (NET). The discrepancies of behavior code or coding system exist among WHO, ENETS, AJCC and KCD. Also, there were differences in the perception for topographic coding system between clinicians and pathologists. NETs of colorectum were reported with the variable clinical characteristics (especially, metastasis) and long term prognosis from many studies. Especially, risk of metastasis and long term prognosis of small sized NET (<1 cm) had some discrepancies and should be investigated prospectively. Therefore, the consensus about topographic codes of NET should be needed with multidisplinary approach among gastroenterologists, pathologists and surgeons. (Intest Res 2013;11:14-22)

Citations

Citations to this article as recorded by  
  • Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors
    Hoonsub So, Su Hyun Yoo, Seungbong Han, Gwang-un Kim, Myeongsook Seo, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon
    Clinical Endoscopy.2017; 50(6): 585.     CrossRef
  • Diagnostic Coding for Intramucosal Carcinoma and Neuroendocrine Tumor in the Colorectum: Proposal for Avoiding Confusing Coding in Korea
    Dong Soo Han, Jin Hee Sohn, Jeong-Sik Byeon, Hwang Choi, Joon Mee Kim
    Clinical Endoscopy.2015; 48(3): 216.     CrossRef
  • Highlights from the 50th Seminar of the Korean Society of Gastrointestinal Endoscopy
    Eun Young Kim, Il Ju Choi, Kwang An Kwon, Ji Kon Ryu, Seok Ho Dong, Ki Baik Hahm
    Clinical Endoscopy.2014; 47(4): 285.     CrossRef
  • 2,579 View
  • 29 Download
  • 3 Crossref
Close layer
Original Articles
Comparison of Bowel Preparation Quality between Clear-liquid Diet and No Diet Restriction
Woo Shin Jeong, Dong Il Park, Hyo Sun Seok, Seong Eun Kim, Suck-Ho Lee, Chang Kyun Lee, Chang Soo Eun, Dong Soo Han
Intest Res 2012;10(3):272-279.   Published online July 31, 2012
DOI: https://doi.org/10.5217/ir.2012.10.3.272
AbstractAbstract PDF
Background/Aims
Adequate bowel preparation is essential for full visualization of colonic mucosa because detection of small polyps and neoplasms depends on the quality of bowel cleansing. The aims of this study were to compare the efficacy, tolerability of preparation and side effect between two groups: clear-liquid diet with polyethylene glycol (PEG) solution versus no diet restriction with PEG solution. Methods: This was a randomized single-blind prospective study. A total of 330 patients were randomly assigned to receive either 2 L PEG solution with a clear-liquid diet on the day before colonoscopy and another 2 L PEG solution on the day of the procedure (group 1) or 2 L PEG solution with a general diet on the day before colonoscopy and another 2 L PEG solution on the day of the procedure (group 2). Results: 162 patients were assigned to group 1 and 168 patients to group 2. The satisfactory quality of bowel preparation was not significantly different between the two groups (80.2%, 78.6%, P=0.707). Patient's compliance of the clear-liquid diet in group 1 was 50%. The satisfactory quality of bowel preparation was weakly better when the clear-liquid diet was given 2 or 3 times a day (group 1A) than 0 or once a day (group 1B) (74.1%, 86.4%, P=0.048). The tolerability of the PEG solution and side effects of preparation were not significantly different in the two groups (P=0.573, 0.686). Conclusions: Bowel preparation with no diet restriction and split-dose PEG solution was similar to preparation with a clear-liquid diet in efficacy, tolerability and side effect. Therefore, the use of the clear-liquid diet protocol should improve patient's compliance. (Intest Res 2012;10: 0-279)

Citations

Citations to this article as recorded by  
  • Comparative Study on Bowel Preparation Efficacy of Ascorbic Acid Containing Polyethylene Glycol by Adding Either Simethicone or 1 L of Water in Health Medical Examination Patients: A Prospective Randomized Controlled Study
    Se Hwan Yeo, Jae Hoon Kwak, Yeo Un Kim, Tae Ho Kwon, Jeong Bae Park, Jun Hyung Park, Yong Kook Lee, Yun Jeong Lim, Chang Heon Yang
    The Korean Journal of Gastroenterology.2016; 67(4): 189.     CrossRef
  • 2,491 View
  • 22 Download
  • 1 Crossref
Close layer
Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients
Kyung Hee Hyun, Suck-Ho Lee, Jae Min Shin, Dong Il Park, Chang Kyun Lee, Jeong Eun Shin, Chang Soo Eun, Kyu Chan Huh, Young Hwangbo
Intest Res 2012;10(3):244-250.   Published online July 31, 2012
DOI: https://doi.org/10.5217/ir.2012.10.3.244
AbstractAbstract PDF
Background/Aims
The most important adverse effect of azathioprine (AZA) is bone marrow toxicity (BMT). Many physicians have preferred a gradual dose increment (GDI) policy for the prevention of BMT. The aim of this study was to evaluate the efficacy of GDI for the prevention of AZA-induced BMT in inflammatory bowel disease (IBD) patients. Methods: The medical records of IBD patients who received AZA in 6 university hospitals were reviewed. The patients were divided into two groups: the GDI group (initial dose <1.5 mg/kg, gradually increased to a therapeutic dose) and the non-GDI group (initial therapeutic dose ≥2 mg/kg). Results: A total of 308 patients were enrolled (male to female ratio, 1:2.3; mean age, 34.91±14.19 years; ulcerative colitis, 43.5%; Crohn's disease, 55.2%; and intermediate colitis, 1.3%). The overall incidence of BMT was 16.2% (50/308). BMT developed most frequently between fourth to eighth week (26%, 13/50). The rate of BMT of the non-GDI group was significantly higher than that of the GDI group (27.5%, 11/40 vs. 14.6%, 39/268, P=0.038). A multivariate analysis showed that the only factor related to BMT was a non-GDI policy (P=0.036; odds ratio, 2.41; 95% confidence interval, 1.06-5.49). Conclusions: A GDI policy could be useful for reducing AZA-induced BMT in Korean IBD patients. (Intest Res 2012;10: 0-250)

Citations

Citations to this article as recorded by  
  • Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)
    Kang-Moon Lee, You Sun Kim, Geom Seog Seo, Tae Oh Kim, Suk-Kyun Yang
    Intestinal Research.2015; 13(3): 193.     CrossRef
  • Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease
    Geom Seog Seo
    The Korean Journal of Gastroenterology.2013; 62(2): 83.     CrossRef
  • How Should Azathioprine Be Dosed in Crohn's Disease? A Novel Strategy of Maximum Dose-titration Based on the Lower Limit of Leukocyte Count and Tolerability
    Chang Sup Lim, Won Moon, Seun Ja Park, Moo In Park, Jeong Moon Choi, Jae Hoon Yoo, Jong Bin Kim, Jun Sik Lee
    The Korean Journal of Gastroenterology.2013; 62(2): 111.     CrossRef
  • 2,597 View
  • 19 Download
  • 3 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP